Global Preclinical Imaging Market: By Product Type, By Application, By End User By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1150
  • Number of Pages: 420
  • Table/Charts : Yes
  • June, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10054
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Preclinical imaging involves the use of advanced imaging technologies to study biological processes in animal models before clinical trials in humans. This field employs techniques such as MRI, PET, CT, and optical imaging to visualize and monitor the anatomy, physiology, and molecular activities within these models. Preclinical imaging provides crucial insights into disease mechanisms, drug efficacy, and safety, allowing researchers to gather detailed, real-time data on how new treatments interact with living systems. By enabling non-invasive, precise observation of biological changes, preclinical imaging plays a vital role in the early stages of drug development, helping to identify promising therapeutic candidates and streamline the path to clinical application.

The demand for preclinical imaging is driven by the need for precise, non-invasive visualization of biological processes in animal models, essential for advancing drug development and medical research. Technological advancements in imaging modalities such as MRI, PET, and CT have significantly improved the accuracy and detail of preclinical studies. The rising prevalence of chronic diseases and the growing focus on personalized medicine further fuel this demand, as detailed imaging is crucial for understanding disease mechanisms and evaluating therapeutic efficacy. Additionally, stringent regulatory requirements for drug approval necessitate comprehensive preclinical imaging to ensure safety and effectiveness, making it a critical component of the pharmaceutical and biotechnology research pipeline. In terms of revenue, the global preclinical imaging market was worth US$ 3.8 Bn in 2023, anticipated to witness CAGR of 5.2% during 2024 – 2034.

Global Preclinical Imaging Market Dynamics

Technological Advancements: Innovations in imaging technologies, such as high-resolution MRI, PET, CT, and optical imaging, enhance the accuracy and efficiency of preclinical studies. These advancements enable more detailed visualization of biological processes, driving demand for state-of-the-art imaging systems. Growth in emerging economies, with increased focus on healthcare infrastructure and research capabilities, presents new opportunities for market expansion.

Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, necessitates extensive preclinical research to develop effective treatments, thus boosting the demand for preclinical imaging. The global increase in the elderly population contributes to the prevalence of age-related diseases, leading to heightened demand for preclinical imaging in the development of geriatric therapies.

Pharmaceutical and Biotechnology R&D: The robust pipeline of new drug candidates and therapeutic interventions in the pharmaceutical and biotechnology sectors fuels the need for comprehensive preclinical imaging to evaluate the safety and efficacy of these innovations. Strategic collaborations and partnerships among academic institutions, research organizations, and industry players promote the development and adoption of cutting-edge imaging technologies, further driving market dynamics.

Regulatory Requirements: Stringent regulatory guidelines for drug approval mandate thorough preclinical testing, including imaging studies, to ensure drug safety and effectiveness, thereby driving market growth. Increased investment in biomedical research by governments and private entities supports the expansion of preclinical imaging capabilities, fostering market growth.

Oncology Segment has Garnered Major Market Share in the Global Preclinical Imaging Market During the Forecast Period (2024 – 2034).

Oncology research is a significant driver of the demand for preclinical imaging, fueled by the urgent need to develop more effective cancer treatments. Preclinical imaging technologies such as MRI, PET, and CT scans are pivotal in visualizing and tracking tumor development, metastasis, and response to therapies in animal models. These advanced imaging methods provide detailed, real-time insights into the biological behavior of cancers, enabling researchers to better understand tumor biology and the efficacy of new oncologic drugs. The rising incidence of cancer worldwide intensifies the pressure to discover novel therapies, thus amplifying the need for thorough preclinical evaluations. Moreover, the push for personalized medicine in oncology necessitates precise imaging to identify specific biomarkers and tailor treatments accordingly. As the complexity of cancer treatments increases, so does the reliance on sophisticated preclinical imaging to guide drug development, optimize therapeutic strategies, and ultimately improve patient outcomes.

By End User Pharmaceutical and Biotechnology Companies Segment had the Highest Share in the Global Preclinical Imaging Market in 2023.

Pharmaceutical and biotechnology companies are key drivers of the demand for preclinical imaging due to their relentless pursuit of innovative drug development and therapeutic solutions. These companies rely on advanced imaging technologies, such as MRI, PET, and CT scans, to obtain detailed insights into the efficacy and safety of new compounds in animal models before proceeding to human trials. The precise data garnered from these imaging modalities are crucial for understanding disease mechanisms, optimizing drug candidates, and predicting clinical outcomes. Moreover, the rising prevalence of chronic and complex diseases necessitates more comprehensive preclinical studies, further escalating the need for sophisticated imaging techniques. Additionally, stringent regulatory standards require thorough preclinical validation to minimize risks and enhance the likelihood of successful clinical trials. As these companies strive to expedite drug discovery and development processes, the demand for cutting-edge preclinical imaging continues to grow, ensuring high-quality, cost-effective research outcomes.

By Region, North America Dominated the Global Preclinical Imaging Market in 2023.

The demand for preclinical imaging in North America is driven by several key factors, primarily advancements in medical research and drug development. This region’s robust pharmaceutical and biotechnology sectors rely heavily on preclinical imaging to visualize, monitor, and understand biological processes in animal models before human trials. Innovations in imaging technologies, such as MRI, PET, and CT scans, have enhanced the precision and reliability of data, leading to more effective and targeted therapeutic interventions. Additionally, the increasing prevalence of chronic diseases and the aging population have spurred the need for novel treatments, further boosting the demand for comprehensive preclinical studies. Regulatory requirements for drug approval and the emphasis on reducing clinical trial failures also contribute significantly to this demand, as thorough preclinical imaging can help identify potential issues early in the development pipeline, ultimately saving time and resources.

Competitive Landscape: Global Preclinical Imaging Market:

  • Agilent Technologies
  • Bruker Corporation
  • General Electric (GE)
  • Mediso Ltd.
  • MILabs B.V.
  • Molecubes
  • MR Solutions
  • PerkinElmer, Inc.
  • Siemens A.G.
  • TriFoil Imaging
  • VisualSonics Inc. (Fujifilm)
  • Other Industry Participants

Global Preclinical Imaging Market Scope

Report Specifications Details
Market Revenue in 2023 US$ 3.8 Bn
Market Size Forecast by 2034 US$ 6.6 Bn
Growth Rate (CAGR) 5.2%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Product Type, By Application, By End User By Region
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Agilent Technologies, Bruker Corporation, General Electric (GE), Mediso Ltd., MILabs B.V., Molecubes, MR Solutions, PerkinElmer, Inc., Siemens A.G., TriFoil Imaging, VisualSonics Inc. (Fujifilm)
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

Global Preclinical Imaging Market

By Product Type

  • Imaging systems
    • Optical imaging systems
      • Bioluminescence imaging systems
      • Fluorescence imaging systems
      • Other optical imaging systems
    • Nuclear imaging systems
      • micro-pet imaging systems
        • Standalone pet imaging systems
        • Pet/CT imaging systems
        • Pet/MRI imaging systems
      • Micro-spect imaging systems
        • standalone spet imaging systems
        • spet/ct imaging systems
        • spet/ MRI imaging systems
      • Trimodality (spect/pet/ct) imaging systems
    • Micro-MRI systems
    • Micro-ultrasound systems
    • Micro-ct systems
    • Photoacoustic imaging systems
    • Magnetic particle imaging (mpi) systems
  • Reagents
    • Preclinical optical imaging reagents
    • Preclinical bioluminescent imaging reagents
      • Luciferins
      • Coelenterazne
      • Furimazine
    • Preclinical fluorescent imaging reagents
      • Green fluorescent proteins
      • Red fluorescent proteins
      • Infrared dyes
    • Preclinical nuclear imaging reagents
      • Preclinical pet tracers
        • Fluorine-18-based preclinical pet tracers
        • Carbon-11-based preclinical pet tracers
        • Copper-64-based preclinical pet tracers
        • Other pet tracers
      • Preclinical spect probes
        • Technetium-99m-based preclinical spect probes
        • Iodine-131-based preclinical spect probes
        • Gallium-67-based preclinical spect probes
        • Thallium-201-based preclinical spect probes
        • Other spect probes
      • Preclinical MRI contrast agents
        • Gadolinium-based preclinical contrast agents
        • Iron-based preclinical contrast agents
        • Manganese-based preclinical contrast agents
      • Preclinical ultrasound contrast agents
      • Preclinical CT contrast agents
        • Iodine-based preclinical ct contrast agents
        • Barium-based preclinical ct contrast agents
        • Gold nanoparticles
        • Gastrografin-based preclinical ct contrast agents
      • Software

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Infectious diseases
  • Immunology & inflammation
  • Other Applications

By End User

  • Pharmaceutical & biotechnology companies
  • Academic & research centers
  • Imaging centers
  • Other end users

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

 Report Layout:

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022
1.2.2.Base Year: 2023
1.2.3.Forecast Years: 2024 – 2034
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Preclinical Imaging Market
6.Market Synopsis: Preclinical Imaging Market
7.Preclinical Imaging Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in Preclinical Imaging Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Preclinical Imaging Market
7.6.Industry Gross Margin Overview
7.7.Porter’s Five Force Analysis
7.8.Impact of Covid-19 on Preclinical Imaging Market
7.9.PESTEL Analysis
7.10.Value Chain Analysis
7.11.Pricing Analysis, By Region (2023)
7.11.1.North America
7.11.2.Europe
7.11.3.Asia Pacific
7.11.4.Middle East and Africa
7.11.5.Latin America
8.Global Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global Preclinical Imaging Market Revenue (US$ Mn)
8.2.Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
8.2.1.Imaging systems (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Optical imaging systems, Nuclear imaging systems, Micro-MRI systems, Micro-ultrasound systems, Micro-ct systems, Photoacoustic imaging systems, Magnetic particle imaging (mpi) systems)
8.2.1.1.Optical imaging systems
8.2.1.1.1.Bioluminescence imaging systems
8.2.1.1.2.Fluorescence imaging systems
8.2.1.1.3.Other optical imaging systems
8.2.1.2.Nuclear imaging systems
8.2.1.2.1.micro-pet imaging systems
8.2.1.2.2.Micro-spect imaging systems
8.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
8.2.1.3.Micro-MRI systems
8.2.1.4.Micro-ultrasound systems
8.2.1.5.Micro-ct systems
8.2.1.6.Photoacoustic imaging systems
8.2.1.7.Magnetic particle imaging (mpi) systems
8.2.2.Reagents (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Preclinical optical imaging reagents, Preclinical bioluminescent imaging reagents, Preclinical fluorescent imaging reagents, Preclinical nuclear imaging reagents, Preclinical MRI contrast agents, Preclinical ultrasound contrast agents, Preclinical CT contrast agents)
8.2.2.1.Preclinical optical imaging reagents
8.2.2.2.Preclinical bioluminescent imaging reagents
8.2.2.2.1.Luciferins
8.2.2.2.2.Coelenterazne
8.2.2.2.3.Furimazine
8.2.2.3.Preclinical fluorescent imaging reagents
8.2.2.3.1.Green fluorescent proteins
8.2.2.3.2.Red fluorescent proteins
8.2.2.3.3.Infrared dyes
8.2.2.4.Preclinical nuclear imaging reagents
8.2.2.4.1.Preclinical pet tracers
8.2.2.4.2.Preclinical spect probes
8.2.2.5.Preclinical MRI contrast agents
8.2.2.5.1.Gadolinium-based preclinical contrast agents
8.2.2.5.2.Iron-based preclinical contrast agents
8.2.2.5.3.Manganese-based preclinical contrast agents
8.2.2.6.Preclinical ultrasound contrast agents
8.2.2.7.Preclinical CT contrast agents
8.2.2.7.1.Iodine-based preclinical ct contrast agents
8.2.2.7.2.Barium-based preclinical ct contrast agents
8.2.2.7.3.Gold nanoparticles
8.2.2.7.4.Gastrografin-based preclinical ct contrast agents
8.2.3.Software
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2016 – 2023
8.2.3.3.Market Forecast, 2024 – 2034
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2016 – 2023
8.2.3.5.1.2.Market Forecast, 2024 – 2034
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2016 – 2023
8.2.3.5.2.2.Market Forecast, 2024 – 2034
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2016 – 2023
8.2.3.5.3.2.Market Forecast, 2024 – 2034
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2016 – 2023
8.2.3.5.4.2.Market Forecast, 2024 – 2034
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2016 – 2023
8.2.3.5.5.2.Market Forecast, 2024 – 2034
8.3.Key Segment for Channeling Investments
8.3.1.By Product Type
9.Global Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
9.1.Overview
9.2.Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1.Oncology
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2016 – 2023
9.2.1.3.Market Forecast, 2024 – 2034
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023
9.2.1.5.1.2.Market Forecast, 2024 – 2034
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023
9.2.1.5.2.2.Market Forecast, 2024 – 2034
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023
9.2.1.5.3.2.Market Forecast, 2024 – 2034
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023
9.2.1.5.4.2.Market Forecast, 2024 – 2034
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023
9.2.1.5.5.2.Market Forecast, 2024 – 2034
9.2.2.Cardiology
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2016 – 2023
9.2.2.3.Market Forecast, 2024 – 2034
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023
9.2.2.5.1.2.Market Forecast, 2024 – 2034
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023
9.2.2.5.2.2.Market Forecast, 2024 – 2034
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023
9.2.2.5.3.2.Market Forecast, 2024 – 2034
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023
9.2.2.5.4.2.Market Forecast, 2024 – 2034
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023
9.2.2.5.5.2.Market Forecast, 2024 – 2034
9.2.3.Neurology
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2016 – 2023
9.2.3.3.Market Forecast, 2024 – 2034
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023
9.2.3.5.1.2.Market Forecast, 2024 – 2034
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023
9.2.3.5.2.2.Market Forecast, 2024 – 2034
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023
9.2.3.5.3.2.Market Forecast, 2024 – 2034
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023
9.2.3.5.4.2.Market Forecast, 2024 – 2034
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023
9.2.3.5.5.2.Market Forecast, 2024 – 2034
9.2.4.Infectious diseases
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2016 – 2023
9.2.4.3.Market Forecast, 2024 – 2034
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2016 – 2023
9.2.4.5.1.2.Market Forecast, 2024 – 2034
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2016 – 2023
9.2.4.5.2.2.Market Forecast, 2024 – 2034
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2016 – 2023
9.2.4.5.3.2.Market Forecast, 2024 – 2034
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2016 – 2023
9.2.4.5.4.2.Market Forecast, 2024 – 2034
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2016 – 2023
9.2.4.5.5.2.Market Forecast, 2024 – 2034
9.2.5.Immunology and inflammation
9.2.5.1.Definition
9.2.5.2.Market Estimation and Penetration, 2016 – 2023
9.2.5.3.Market Forecast, 2024 – 2034
9.2.5.4.Compound Annual Growth Rate (CAGR)
9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2016 – 2023
9.2.5.5.1.2.Market Forecast, 2024 – 2034
9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2016 – 2023
9.2.5.5.2.2.Market Forecast, 2024 – 2034
9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2016 – 2023
9.2.5.5.3.2.Market Forecast, 2024 – 2034
9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2016 – 2023
9.2.5.5.4.2.Market Forecast, 2024 – 2034
9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2016 – 2023
9.2.5.5.5.2.Market Forecast, 2024 – 2034
9.2.6.Other Applications
9.2.6.1.Definition
9.2.6.2.Market Estimation and Penetration, 2016 – 2023
9.2.6.3.Market Forecast, 2024 – 2034
9.2.6.4.Compound Annual Growth Rate (CAGR)
9.2.6.5.Regional Bifurcation
9.2.6.5.1.North America
9.2.6.5.1.1.Market Estimation, 2016 – 2023
9.2.6.5.1.2.Market Forecast, 2024 – 2034
9.2.6.5.2.Europe
9.2.6.5.2.1.Market Estimation, 2016 – 2023
9.2.6.5.2.2.Market Forecast, 2024 – 2034
9.2.6.5.3.Asia Pacific
9.2.6.5.3.1.Market Estimation, 2016 – 2023
9.2.6.5.3.2.Market Forecast, 2024 – 2034
9.2.6.5.4.Middle East and Africa
9.2.6.5.4.1.Market Estimation, 2016 – 2023
9.2.6.5.4.2.Market Forecast, 2024 – 2034
9.2.6.5.5.Latin America
9.2.6.5.5.1.Market Estimation, 2016 – 2023
9.2.6.5.5.2.Market Forecast, 2024 – 2034
9.3.Key Segment for Channeling Investments
9.3.1.By Application
10.Global Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
10.1.Overview
10.2.Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
10.2.1.Pharmaceutical and Biotechnology companies
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2016 – 2023
10.2.1.3.Market Forecast, 2024 – 2034
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2016 – 2023
10.2.1.5.1.2.Market Forecast, 2024 – 2034
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2016 – 2023
10.2.1.5.2.2.Market Forecast, 2024 – 2034
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2016 – 2023
10.2.1.5.3.2.Market Forecast, 2024 – 2034
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2016 – 2023
10.2.1.5.4.2.Market Forecast, 2024 – 2034
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2016 – 2023
10.2.1.5.5.2.Market Forecast, 2024 – 2034
10.2.2.Academic and Research Centers
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2016 – 2023
10.2.2.3.Market Forecast, 2024 – 2034
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2016 – 2023
10.2.2.5.1.2.Market Forecast, 2024 – 2034
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2016 – 2023
10.2.2.5.2.2.Market Forecast, 2024 – 2034
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2016 – 2023
10.2.2.5.3.2.Market Forecast, 2024 – 2034
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2016 – 2023
10.2.2.5.4.2.Market Forecast, 2024 – 2034
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2016 – 2023
10.2.2.5.5.2.Market Forecast, 2024 – 2034
10.2.3.Imaging centers
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2016 – 2023
10.2.3.3.Market Forecast, 2024 – 2034
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2016 – 2023
10.2.3.5.1.2.Market Forecast, 2024 – 2034
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2016 – 2023
10.2.3.5.2.2.Market Forecast, 2024 – 2034
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2016 – 2023
10.2.3.5.3.2.Market Forecast, 2024 – 2034
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2016 – 2023
10.2.3.5.4.2.Market Forecast, 2024 – 2034
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2016 – 2023
10.2.3.5.5.2.Market Forecast, 2024 – 2034
10.2.4.Other end users
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2016 – 2023
10.2.4.3.Market Forecast, 2024 – 2034
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2016 – 2023
10.2.4.5.1.2.Market Forecast, 2024 – 2034
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2016 – 2023
10.2.4.5.2.2.Market Forecast, 2024 – 2034
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2016 – 2023
10.2.4.5.3.2.Market Forecast, 2024 – 2034
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2016 – 2023
10.2.4.5.4.2.Market Forecast, 2024 – 2034
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2016 – 2023
10.2.4.5.5.2.Market Forecast, 2024 – 2034
10.3.Key Segment for Channeling Investments
10.3.1.By End User
11.North America Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
11.1.Overview
11.1.1.North America Preclinical Imaging Market Revenue (US$ Mn)
11.2.North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
11.2.1.Imaging systems
11.2.1.1.Optical imaging systems
11.2.1.1.1.Bioluminescence imaging systems
11.2.1.1.2.Fluorescence imaging systems
11.2.1.1.3.Other optical imaging systems
11.2.1.2.Nuclear imaging systems
11.2.1.2.1.micro-pet imaging systems
11.2.1.2.2.Micro-spect imaging systems
11.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
11.2.1.3.Micro-MRI systems
11.2.1.4.Micro-ultrasound systems
11.2.1.5.Micro-ct systems
11.2.1.6.Photoacoustic imaging systems
11.2.1.7.Magnetic particle imaging (mpi) systems
11.2.2.Reagents
11.2.2.1.Preclinical optical imaging reagents
11.2.2.2.Preclinical bioluminescent imaging reagents
11.2.2.2.1.Luciferins
11.2.2.2.2.Coelenterazne
11.2.2.2.3.Furimazine
11.2.2.3.Preclinical fluorescent imaging reagents
11.2.2.3.1.Green fluorescent proteins
11.2.2.3.2.Red fluorescent proteins
11.2.2.3.3.Infrared dyes
11.2.2.4.Preclinical nuclear imaging reagents
11.2.2.4.1.Preclinical pet tracers
11.2.2.4.2.Preclinical spect probes
11.2.2.5.Preclinical MRI contrast agents
11.2.2.5.1.Gadolinium-based preclinical contrast agents
11.2.2.5.2.Iron-based preclinical contrast agents
11.2.2.5.3.Manganese-based preclinical contrast agents
11.2.2.6.Preclinical ultrasound contrast agents
11.2.2.7.Preclinical CT contrast agents
11.2.2.7.1.Iodine-based preclinical ct contrast agents
11.2.2.7.2.Barium-based preclinical ct contrast agents
11.2.2.7.3.Gold nanoparticles
11.2.2.7.4.Gastrografin-based preclinical ct contrast agents
11.2.3.Software
11.3.North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1.Oncology
11.3.2.Cardiology
11.3.3.Neurology
11.3.4.Infectious diseases
11.3.5.Immunology and inflammation
11.3.6.Other Applications
11.4.North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
11.4.1.Pharmaceutical and Biotechnology companies
11.4.2.Academic and Research Centers
11.4.3.Imaging centers
11.4.4.Other end users
11.5.North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1.U.S
11.5.1.1.U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.1.1.1.Imaging systems
11.5.1.1.1.1.Optical imaging systems
11.5.1.1.1.1.1.Bioluminescence imaging systems
11.5.1.1.1.1.2.Fluorescence imaging systems
11.5.1.1.1.1.3.Other optical imaging systems
11.5.1.1.1.2.Nuclear imaging systems
11.5.1.1.1.2.1.micro-pet imaging systems
11.5.1.1.1.2.2.Micro-spect imaging systems
11.5.1.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
11.5.1.1.1.3.Micro-MRI systems
11.5.1.1.1.4.Micro-ultrasound systems
11.5.1.1.1.5.Micro-ct systems
11.5.1.1.1.6.Photoacoustic imaging systems
11.5.1.1.1.7.Magnetic particle imaging (mpi) systems
11.5.1.1.2.Reagents
11.5.1.1.2.1.Preclinical optical imaging reagents
11.5.1.1.2.2.Preclinical bioluminescent imaging reagents
11.5.1.1.2.2.1.Luciferins
11.5.1.1.2.2.2.Coelenterazne
11.5.1.1.2.2.3.Furimazine
11.5.1.1.2.3.Preclinical fluorescent imaging reagents
11.5.1.1.2.3.1.Green fluorescent proteins
11.5.1.1.2.3.2.Red fluorescent proteins
11.5.1.1.2.3.3.Infrared dyes
11.5.1.1.2.4.Preclinical nuclear imaging reagents
11.5.1.1.2.4.1.Preclinical pet tracers
11.5.1.1.2.4.2.Preclinical spect probes
11.5.1.1.2.5.Preclinical MRI contrast agents
11.5.1.1.2.5.1.Gadolinium-based preclinical contrast agents
11.5.1.1.2.5.2.Iron-based preclinical contrast agents
11.5.1.1.2.5.3.Manganese-based preclinical contrast agents
11.5.1.1.2.6.Preclinical ultrasound contrast agents
11.5.1.1.2.7.Preclinical CT contrast agents
11.5.1.1.2.7.1.Iodine-based preclinical ct contrast agents
11.5.1.1.2.7.2.Barium-based preclinical ct contrast agents
11.5.1.1.2.7.3.Gold nanoparticles
11.5.1.1.2.7.4.Gastrografin-based preclinical ct contrast agents
11.5.1.1.3.Software
11.5.1.2.U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.2.1.Oncology
11.5.1.2.2.Cardiology
11.5.1.2.3.Neurology
11.5.1.2.4.Infectious diseases
11.5.1.2.5.Immunology and inflammation
11.5.1.2.6.Other Applications
11.5.1.3.U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
11.5.1.3.1.Pharmaceutical and Biotechnology companies
11.5.1.3.2.Academic and Research Centers
11.5.1.3.3.Imaging centers
11.5.1.3.4.Other end users
11.5.2.Canada
11.5.2.1.Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.2.1.1.Imaging systems
11.5.2.1.1.1.Optical imaging systems
11.5.2.1.1.1.1.Bioluminescence imaging systems
11.5.2.1.1.1.2.Fluorescence imaging systems
11.5.2.1.1.1.3.Other optical imaging systems
11.5.2.1.1.2.Nuclear imaging systems
11.5.2.1.1.2.1.micro-pet imaging systems
11.5.2.1.1.2.2.Micro-spect imaging systems
11.5.2.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
11.5.2.1.1.3.Micro-MRI systems
11.5.2.1.1.4.Micro-ultrasound systems
11.5.2.1.1.5.Micro-ct systems
11.5.2.1.1.6.Photoacoustic imaging systems
11.5.2.1.1.7.Magnetic particle imaging (mpi) systems
11.5.2.1.2.Reagents
11.5.2.1.2.1.Preclinical optical imaging reagents
11.5.2.1.2.2.Preclinical bioluminescent imaging reagents
11.5.2.1.2.2.1.Luciferins
11.5.2.1.2.2.2.Coelenterazne
11.5.2.1.2.2.3.Furimazine
11.5.2.1.2.3.Preclinical fluorescent imaging reagents
11.5.2.1.2.3.1.Green fluorescent proteins
11.5.2.1.2.3.2.Red fluorescent proteins
11.5.2.1.2.3.3.Infrared dyes
11.5.2.1.2.4.Preclinical nuclear imaging reagents
11.5.2.1.2.4.1.Preclinical pet tracers
11.5.2.1.2.4.2.Preclinical spect probes
11.5.2.1.2.5.Preclinical MRI contrast agents
11.5.2.1.2.5.1.Gadolinium-based preclinical contrast agents
11.5.2.1.2.5.2.Iron-based preclinical contrast agents
11.5.2.1.2.5.3.Manganese-based preclinical contrast agents
11.5.2.1.2.6.Preclinical ultrasound contrast agents
11.5.2.1.2.7.Preclinical CT contrast agents
11.5.2.1.2.7.1.Iodine-based preclinical ct contrast agents
11.5.2.1.2.7.2.Barium-based preclinical ct contrast agents
11.5.2.1.2.7.3.Gold nanoparticles
11.5.2.1.2.7.4.Gastrografin-based preclinical ct contrast agents
11.5.2.1.3.Software
11.5.2.2.Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1.Oncology
11.5.2.2.2.Cardiology
11.5.2.2.3.Neurology
11.5.2.2.4.Infectious diseases
11.5.2.2.5.Immunology and inflammation
11.5.2.2.6.Other Applications
11.5.2.3.Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
11.5.2.3.1.Pharmaceutical and Biotechnology companies
11.5.2.3.2.Academic and Research Centers
11.5.2.3.3.Imaging centers
11.5.2.3.4.Other end users
11.5.3.Mexico
11.5.3.1.Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.3.1.1.Imaging systems
11.5.3.1.1.1.Optical imaging systems
11.5.3.1.1.1.1.Bioluminescence imaging systems
11.5.3.1.1.1.2.Fluorescence imaging systems
11.5.3.1.1.1.3.Other optical imaging systems
11.5.3.1.1.2.Nuclear imaging systems
11.5.3.1.1.2.1.micro-pet imaging systems
11.5.3.1.1.2.2.Micro-spect imaging systems
11.5.3.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
11.5.3.1.1.3.Micro-MRI systems
11.5.3.1.1.4.Micro-ultrasound systems
11.5.3.1.1.5.Micro-ct systems
11.5.3.1.1.6.Photoacoustic imaging systems
11.5.3.1.1.7.Magnetic particle imaging (mpi) systems
11.5.3.1.2.Reagents
11.5.3.1.2.1.Preclinical optical imaging reagents
11.5.3.1.2.2.Preclinical bioluminescent imaging reagents
11.5.3.1.2.2.1.Luciferins
11.5.3.1.2.2.2.Coelenterazne
11.5.3.1.2.2.3.Furimazine
11.5.3.1.2.3.Preclinical fluorescent imaging reagents
11.5.3.1.2.3.1.Green fluorescent proteins
11.5.3.1.2.3.2.Red fluorescent proteins
11.5.3.1.2.3.3.Infrared dyes
11.5.3.1.2.4.Preclinical nuclear imaging reagents
11.5.3.1.2.4.1.Preclinical pet tracers
11.5.3.1.2.4.2.Preclinical spect probes
11.5.3.1.2.5.Preclinical MRI contrast agents
11.5.3.1.2.5.1.Gadolinium-based preclinical contrast agents
11.5.3.1.2.5.2.Iron-based preclinical contrast agents
11.5.3.1.2.5.3.Manganese-based preclinical contrast agents
11.5.3.1.2.6.Preclinical ultrasound contrast agents
11.5.3.1.2.7.Preclinical CT contrast agents
11.5.3.1.2.7.1.Iodine-based preclinical ct contrast agents
11.5.3.1.2.7.2.Barium-based preclinical ct contrast agents
11.5.3.1.2.7.3.Gold nanoparticles
11.5.3.1.2.7.4.Gastrografin-based preclinical ct contrast agents
11.5.3.1.3.Software
11.5.3.2.Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.2.1.Oncology
11.5.3.2.2.Cardiology
11.5.3.2.3.Neurology
11.5.3.2.4.Infectious diseases
11.5.3.2.5.Immunology and inflammation
11.5.3.2.6.Other Applications
11.5.3.3.Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
11.5.3.3.1.Pharmaceutical and Biotechnology companies
11.5.3.3.2.Academic and Research Centers
11.5.3.3.3.Imaging centers
11.5.3.3.4.Other end users
11.5.4.Rest of North America
11.5.4.1.Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.4.1.1.Imaging systems
11.5.4.1.1.1.Optical imaging systems
11.5.4.1.1.1.1.Bioluminescence imaging systems
11.5.4.1.1.1.2.Fluorescence imaging systems
11.5.4.1.1.1.3.Other optical imaging systems
11.5.4.1.1.2.Nuclear imaging systems
11.5.4.1.1.2.1.micro-pet imaging systems
11.5.4.1.1.2.2.Micro-spect imaging systems
11.5.4.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
11.5.4.1.1.3.Micro-MRI systems
11.5.4.1.1.4.Micro-ultrasound systems
11.5.4.1.1.5.Micro-ct systems
11.5.4.1.1.6.Photoacoustic imaging systems
11.5.4.1.1.7.Magnetic particle imaging (mpi) systems
11.5.4.1.2.Reagents
11.5.4.1.2.1.Preclinical optical imaging reagents
11.5.4.1.2.2.Preclinical bioluminescent imaging reagents
11.5.4.1.2.2.1.Luciferins
11.5.4.1.2.2.2.Coelenterazne
11.5.4.1.2.2.3.Furimazine
11.5.4.1.2.3.Preclinical fluorescent imaging reagents
11.5.4.1.2.3.1.Green fluorescent proteins
11.5.4.1.2.3.2.Red fluorescent proteins
11.5.4.1.2.3.3.Infrared dyes
11.5.4.1.2.4.Preclinical nuclear imaging reagents
11.5.4.1.2.4.1.Preclinical pet tracers
11.5.4.1.2.4.2.Preclinical spect probes
11.5.4.1.2.5.Preclinical MRI contrast agents
11.5.4.1.2.5.1.Gadolinium-based preclinical contrast agents
11.5.4.1.2.5.2.Iron-based preclinical contrast agents
11.5.4.1.2.5.3.Manganese-based preclinical contrast agents
11.5.4.1.2.6.Preclinical ultrasound contrast agents
11.5.4.1.2.7.Preclinical CT contrast agents
11.5.4.1.2.7.1.Iodine-based preclinical ct contrast agents
11.5.4.1.2.7.2.Barium-based preclinical ct contrast agents
11.5.4.1.2.7.3.Gold nanoparticles
11.5.4.1.2.7.4.Gastrografin-based preclinical ct contrast agents
11.5.4.1.3.Software
11.5.4.2.Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1.Oncology
11.5.4.2.2.Cardiology
11.5.4.2.3.Neurology
11.5.4.2.4.Infectious diseases
11.5.4.2.5.Immunology and inflammation
11.5.4.2.6.Other Applications
11.5.4.3.Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1.Pharmaceutical and Biotechnology companies
11.5.4.3.2.Academic and Research Centers
11.5.4.3.3.Imaging centers
11.5.4.3.4.Other end users
11.6.Key Segment for Channeling Investments
11.6.1.By Country
11.6.2.By Product Type
11.6.3.By Application
11.6.4.By End User
12.Europe Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
12.1.Overview
12.1.1.Europe Preclinical Imaging Market Revenue (US$ Mn)
12.2.Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.2.1.Imaging systems
12.2.1.1.Optical imaging systems
12.2.1.1.1.Bioluminescence imaging systems
12.2.1.1.2.Fluorescence imaging systems
12.2.1.1.3.Other optical imaging systems
12.2.1.2.Nuclear imaging systems
12.2.1.2.1.micro-pet imaging systems
12.2.1.2.2.Micro-spect imaging systems
12.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.2.1.3.Micro-MRI systems
12.2.1.4.Micro-ultrasound systems
12.2.1.5.Micro-ct systems
12.2.1.6.Photoacoustic imaging systems
12.2.1.7.Magnetic particle imaging (mpi) systems
12.2.2.Reagents
12.2.2.1.Preclinical optical imaging reagents
12.2.2.2.Preclinical bioluminescent imaging reagents
12.2.2.2.1.Luciferins
12.2.2.2.2.Coelenterazne
12.2.2.2.3.Furimazine
12.2.2.3.Preclinical fluorescent imaging reagents
12.2.2.3.1.Green fluorescent proteins
12.2.2.3.2.Red fluorescent proteins
12.2.2.3.3.Infrared dyes
12.2.2.4.Preclinical nuclear imaging reagents
12.2.2.4.1.Preclinical pet tracers
12.2.2.4.2.Preclinical spect probes
12.2.2.5.Preclinical MRI contrast agents
12.2.2.5.1.Gadolinium-based preclinical contrast agents
12.2.2.5.2.Iron-based preclinical contrast agents
12.2.2.5.3.Manganese-based preclinical contrast agents
12.2.2.6.Preclinical ultrasound contrast agents
12.2.2.7.Preclinical CT contrast agents
12.2.2.7.1.Iodine-based preclinical ct contrast agents
12.2.2.7.2.Barium-based preclinical ct contrast agents
12.2.2.7.3.Gold nanoparticles
12.2.2.7.4.Gastrografin-based preclinical ct contrast agents
12.2.3.Software
12.3.Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1.Oncology
12.3.2.Cardiology
12.3.3.Neurology
12.3.4.Infectious diseases
12.3.5.Immunology and inflammation
12.3.6.Other Applications
12.4.Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.4.1.Pharmaceutical and Biotechnology companies
12.4.2.Academic and Research Centers
12.4.3.Imaging centers
12.4.4.Other end users
12.5.Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1.France
12.5.1.1.France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.1.1.1.Imaging systems
12.5.1.1.1.1.Optical imaging systems
12.5.1.1.1.1.1.Bioluminescence imaging systems
12.5.1.1.1.1.2.Fluorescence imaging systems
12.5.1.1.1.1.3.Other optical imaging systems
12.5.1.1.1.2.Nuclear imaging systems
12.5.1.1.1.2.1.micro-pet imaging systems
12.5.1.1.1.2.2.Micro-spect imaging systems
12.5.1.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.1.1.1.3.Micro-MRI systems
12.5.1.1.1.4.Micro-ultrasound systems
12.5.1.1.1.5.Micro-ct systems
12.5.1.1.1.6.Photoacoustic imaging systems
12.5.1.1.1.7.Magnetic particle imaging (mpi) systems
12.5.1.1.2.Reagents
12.5.1.1.2.1.Preclinical optical imaging reagents
12.5.1.1.2.2.Preclinical bioluminescent imaging reagents
12.5.1.1.2.2.1.Luciferins
12.5.1.1.2.2.2.Coelenterazne
12.5.1.1.2.2.3.Furimazine
12.5.1.1.2.3.Preclinical fluorescent imaging reagents
12.5.1.1.2.3.1.Green fluorescent proteins
12.5.1.1.2.3.2.Red fluorescent proteins
12.5.1.1.2.3.3.Infrared dyes
12.5.1.1.2.4.Preclinical nuclear imaging reagents
12.5.1.1.2.4.1.Preclinical pet tracers
12.5.1.1.2.4.2.Preclinical spect probes
12.5.1.1.2.5.Preclinical MRI contrast agents
12.5.1.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.1.1.2.5.2.Iron-based preclinical contrast agents
12.5.1.1.2.5.3.Manganese-based preclinical contrast agents
12.5.1.1.2.6.Preclinical ultrasound contrast agents
12.5.1.1.2.7.Preclinical CT contrast agents
12.5.1.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.1.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.1.1.2.7.3.Gold nanoparticles
12.5.1.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.1.1.3.Software
12.5.1.2.France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1.Oncology
12.5.1.2.2.Cardiology
12.5.1.2.3.Neurology
12.5.1.2.4.Infectious diseases
12.5.1.2.5.Immunology and inflammation
12.5.1.2.6.Other Applications
12.5.1.3.France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1.3.1.Pharmaceutical and Biotechnology companies
12.5.1.3.2.Academic and Research Centers
12.5.1.3.3.Imaging centers
12.5.1.3.4.Other end users
12.5.2.The UK
12.5.2.1.The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.2.1.1.Imaging systems
12.5.2.1.1.1.Optical imaging systems
12.5.2.1.1.1.1.Bioluminescence imaging systems
12.5.2.1.1.1.2.Fluorescence imaging systems
12.5.2.1.1.1.3.Other optical imaging systems
12.5.2.1.1.2.Nuclear imaging systems
12.5.2.1.1.2.1.micro-pet imaging systems
12.5.2.1.1.2.2.Micro-spect imaging systems
12.5.2.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.2.1.1.3.Micro-MRI systems
12.5.2.1.1.4.Micro-ultrasound systems
12.5.2.1.1.5.Micro-ct systems
12.5.2.1.1.6.Photoacoustic imaging systems
12.5.2.1.1.7.Magnetic particle imaging (mpi) systems
12.5.2.1.2.Reagents
12.5.2.1.2.1.Preclinical optical imaging reagents
12.5.2.1.2.2.Preclinical bioluminescent imaging reagents
12.5.2.1.2.2.1.Luciferins
12.5.2.1.2.2.2.Coelenterazne
12.5.2.1.2.2.3.Furimazine
12.5.2.1.2.3.Preclinical fluorescent imaging reagents
12.5.2.1.2.3.1.Green fluorescent proteins
12.5.2.1.2.3.2.Red fluorescent proteins
12.5.2.1.2.3.3.Infrared dyes
12.5.2.1.2.4.Preclinical nuclear imaging reagents
12.5.2.1.2.4.1.Preclinical pet tracers
12.5.2.1.2.4.2.Preclinical spect probes
12.5.2.1.2.5.Preclinical MRI contrast agents
12.5.2.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.2.1.2.5.2.Iron-based preclinical contrast agents
12.5.2.1.2.5.3.Manganese-based preclinical contrast agents
12.5.2.1.2.6.Preclinical ultrasound contrast agents
12.5.2.1.2.7.Preclinical CT contrast agents
12.5.2.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.2.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.2.1.2.7.3.Gold nanoparticles
12.5.2.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.2.1.3.Software
12.5.2.2.The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.2.1.Oncology
12.5.2.2.2.Cardiology
12.5.2.2.3.Neurology
12.5.2.2.4.Infectious diseases
12.5.2.2.5.Immunology and inflammation
12.5.2.2.6.Other Applications
12.5.2.3.The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.2.3.1.Pharmaceutical and Biotechnology companies
12.5.2.3.2.Academic and Research Centers
12.5.2.3.3.Imaging centers
12.5.2.3.4.Other end users
12.5.3.Spain
12.5.3.1.Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.3.1.1.Imaging systems
12.5.3.1.1.1.Optical imaging systems
12.5.3.1.1.1.1.Bioluminescence imaging systems
12.5.3.1.1.1.2.Fluorescence imaging systems
12.5.3.1.1.1.3.Other optical imaging systems
12.5.3.1.1.2.Nuclear imaging systems
12.5.3.1.1.2.1.micro-pet imaging systems
12.5.3.1.1.2.2.Micro-spect imaging systems
12.5.3.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.3.1.1.3.Micro-MRI systems
12.5.3.1.1.4.Micro-ultrasound systems
12.5.3.1.1.5.Micro-ct systems
12.5.3.1.1.6.Photoacoustic imaging systems
12.5.3.1.1.7.Magnetic particle imaging (mpi) systems
12.5.3.1.2.Reagents
12.5.3.1.2.1.Preclinical optical imaging reagents
12.5.3.1.2.2.Preclinical bioluminescent imaging reagents
12.5.3.1.2.2.1.Luciferins
12.5.3.1.2.2.2.Coelenterazne
12.5.3.1.2.2.3.Furimazine
12.5.3.1.2.3.Preclinical fluorescent imaging reagents
12.5.3.1.2.3.1.Green fluorescent proteins
12.5.3.1.2.3.2.Red fluorescent proteins
12.5.3.1.2.3.3.Infrared dyes
12.5.3.1.2.4.Preclinical nuclear imaging reagents
12.5.3.1.2.4.1.Preclinical pet tracers
12.5.3.1.2.4.2.Preclinical spect probes
12.5.3.1.2.5.Preclinical MRI contrast agents
12.5.3.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.3.1.2.5.2.Iron-based preclinical contrast agents
12.5.3.1.2.5.3.Manganese-based preclinical contrast agents
12.5.3.1.2.6.Preclinical ultrasound contrast agents
12.5.3.1.2.7.Preclinical CT contrast agents
12.5.3.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.3.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.3.1.2.7.3.Gold nanoparticles
12.5.3.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.3.1.3.Software
12.5.3.2.Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1.Oncology
12.5.3.2.2.Cardiology
12.5.3.2.3.Neurology
12.5.3.2.4.Infectious diseases
12.5.3.2.5.Immunology and inflammation
12.5.3.2.6.Other Applications
12.5.3.3.Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.3.3.1.Pharmaceutical and Biotechnology companies
12.5.3.3.2.Academic and Research Centers
12.5.3.3.3.Imaging centers
12.5.3.3.4.Other end users
12.5.4.Germany
12.5.4.1.Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.4.1.1.Imaging systems
12.5.4.1.1.1.Optical imaging systems
12.5.4.1.1.1.1.Bioluminescence imaging systems
12.5.4.1.1.1.2.Fluorescence imaging systems
12.5.4.1.1.1.3.Other optical imaging systems
12.5.4.1.1.2.Nuclear imaging systems
12.5.4.1.1.2.1.micro-pet imaging systems
12.5.4.1.1.2.2.Micro-spect imaging systems
12.5.4.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.4.1.1.3.Micro-MRI systems
12.5.4.1.1.4.Micro-ultrasound systems
12.5.4.1.1.5.Micro-ct systems
12.5.4.1.1.6.Photoacoustic imaging systems
12.5.4.1.1.7.Magnetic particle imaging (mpi) systems
12.5.4.1.2.Reagents
12.5.4.1.2.1.Preclinical optical imaging reagents
12.5.4.1.2.2.Preclinical bioluminescent imaging reagents
12.5.4.1.2.2.1.Luciferins
12.5.4.1.2.2.2.Coelenterazne
12.5.4.1.2.2.3.Furimazine
12.5.4.1.2.3.Preclinical fluorescent imaging reagents
12.5.4.1.2.3.1.Green fluorescent proteins
12.5.4.1.2.3.2.Red fluorescent proteins
12.5.4.1.2.3.3.Infrared dyes
12.5.4.1.2.4.Preclinical nuclear imaging reagents
12.5.4.1.2.4.1.Preclinical pet tracers
12.5.4.1.2.4.2.Preclinical spect probes
12.5.4.1.2.5.Preclinical MRI contrast agents
12.5.4.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.4.1.2.5.2.Iron-based preclinical contrast agents
12.5.4.1.2.5.3.Manganese-based preclinical contrast agents
12.5.4.1.2.6.Preclinical ultrasound contrast agents
12.5.4.1.2.7.Preclinical CT contrast agents
12.5.4.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.4.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.4.1.2.7.3.Gold nanoparticles
12.5.4.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.4.1.3.Software
12.5.4.2.Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1.Oncology
12.5.4.2.2.Cardiology
12.5.4.2.3.Neurology
12.5.4.2.4.Infectious diseases
12.5.4.2.5.Immunology and inflammation
12.5.4.2.6.Other Applications
12.5.4.3.Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.4.3.1.Pharmaceutical and Biotechnology companies
12.5.4.3.2.Academic and Research Centers
12.5.4.3.3.Imaging centers
12.5.4.3.4.Other end users
12.5.5.Italy
12.5.5.1.Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.5.1.1.Imaging systems
12.5.5.1.1.1.Optical imaging systems
12.5.5.1.1.1.1.Bioluminescence imaging systems
12.5.5.1.1.1.2.Fluorescence imaging systems
12.5.5.1.1.1.3.Other optical imaging systems
12.5.5.1.1.2.Nuclear imaging systems
12.5.5.1.1.2.1.micro-pet imaging systems
12.5.5.1.1.2.2.Micro-spect imaging systems
12.5.5.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.5.1.1.3.Micro-MRI systems
12.5.5.1.1.4.Micro-ultrasound systems
12.5.5.1.1.5.Micro-ct systems
12.5.5.1.1.6.Photoacoustic imaging systems
12.5.5.1.1.7.Magnetic particle imaging (mpi) systems
12.5.5.1.2.Reagents
12.5.5.1.2.1.Preclinical optical imaging reagents
12.5.5.1.2.2.Preclinical bioluminescent imaging reagents
12.5.5.1.2.2.1.Luciferins
12.5.5.1.2.2.2.Coelenterazne
12.5.5.1.2.2.3.Furimazine
12.5.5.1.2.3.Preclinical fluorescent imaging reagents
12.5.5.1.2.3.1.Green fluorescent proteins
12.5.5.1.2.3.2.Red fluorescent proteins
12.5.5.1.2.3.3.Infrared dyes
12.5.5.1.2.4.Preclinical nuclear imaging reagents
12.5.5.1.2.4.1.Preclinical pet tracers
12.5.5.1.2.4.2.Preclinical spect probes
12.5.5.1.2.5.Preclinical MRI contrast agents
12.5.5.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.5.1.2.5.2.Iron-based preclinical contrast agents
12.5.5.1.2.5.3.Manganese-based preclinical contrast agents
12.5.5.1.2.6.Preclinical ultrasound contrast agents
12.5.5.1.2.7.Preclinical CT contrast agents
12.5.5.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.5.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.5.1.2.7.3.Gold nanoparticles
12.5.5.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.5.1.3.Software
12.5.5.2.Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.2.1.Oncology
12.5.5.2.2.Cardiology
12.5.5.2.3.Neurology
12.5.5.2.4.Infectious diseases
12.5.5.2.5.Immunology and inflammation
12.5.5.2.6.Other Applications
12.5.5.3.Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.5.3.1.Pharmaceutical and Biotechnology companies
12.5.5.3.2.Academic and Research Centers
12.5.5.3.3.Imaging centers
12.5.5.3.4.Other end users
12.5.6.Nordic Countries
12.5.6.1.Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.6.1.1.Imaging systems
12.5.6.1.1.1.Optical imaging systems
12.5.6.1.1.1.1.Bioluminescence imaging systems
12.5.6.1.1.1.2.Fluorescence imaging systems
12.5.6.1.1.1.3.Other optical imaging systems
12.5.6.1.1.2.Nuclear imaging systems
12.5.6.1.1.2.1.micro-pet imaging systems
12.5.6.1.1.2.2.Micro-spect imaging systems
12.5.6.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.6.1.1.3.Micro-MRI systems
12.5.6.1.1.4.Micro-ultrasound systems
12.5.6.1.1.5.Micro-ct systems
12.5.6.1.1.6.Photoacoustic imaging systems
12.5.6.1.1.7.Magnetic particle imaging (mpi) systems
12.5.6.1.2.Reagents
12.5.6.1.2.1.Preclinical optical imaging reagents
12.5.6.1.2.2.Preclinical bioluminescent imaging reagents
12.5.6.1.2.2.1.Luciferins
12.5.6.1.2.2.2.Coelenterazne
12.5.6.1.2.2.3.Furimazine
12.5.6.1.2.3.Preclinical fluorescent imaging reagents
12.5.6.1.2.3.1.Green fluorescent proteins
12.5.6.1.2.3.2.Red fluorescent proteins
12.5.6.1.2.3.3.Infrared dyes
12.5.6.1.2.4.Preclinical nuclear imaging reagents
12.5.6.1.2.4.1.Preclinical pet tracers
12.5.6.1.2.4.2.Preclinical spect probes
12.5.6.1.2.5.Preclinical MRI contrast agents
12.5.6.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.6.1.2.5.2.Iron-based preclinical contrast agents
12.5.6.1.2.5.3.Manganese-based preclinical contrast agents
12.5.6.1.2.6.Preclinical ultrasound contrast agents
12.5.6.1.2.7.Preclinical CT contrast agents
12.5.6.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.6.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.6.1.2.7.3.Gold nanoparticles
12.5.6.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.6.1.3.Software
12.5.6.2.Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.2.1.Oncology
12.5.6.2.2.Cardiology
12.5.6.2.3.Neurology
12.5.6.2.4.Infectious diseases
12.5.6.2.5.Immunology and inflammation
12.5.6.2.6.Other Applications
12.5.6.3.Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1.Pharmaceutical and Biotechnology companies
12.5.6.3.2.Academic and Research Centers
12.5.6.3.3.Imaging centers
12.5.6.3.4.Other end users
12.5.6.4.Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.Denmark
12.5.6.4.2.Finland
12.5.6.4.3.Iceland
12.5.6.4.4.Sweden
12.5.6.4.5.Norway
12.5.7.Benelux Union
12.5.7.1.Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.7.1.1.Imaging systems
12.5.7.1.1.1.Optical imaging systems
12.5.7.1.1.1.1.Bioluminescence imaging systems
12.5.7.1.1.1.2.Fluorescence imaging systems
12.5.7.1.1.1.3.Other optical imaging systems
12.5.7.1.1.2.Nuclear imaging systems
12.5.7.1.1.2.1.micro-pet imaging systems
12.5.7.1.1.2.2.Micro-spect imaging systems
12.5.7.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.7.1.1.3.Micro-MRI systems
12.5.7.1.1.4.Micro-ultrasound systems
12.5.7.1.1.5.Micro-ct systems
12.5.7.1.1.6.Photoacoustic imaging systems
12.5.7.1.1.7.Magnetic particle imaging (mpi) systems
12.5.7.1.2.Reagents
12.5.7.1.2.1.Preclinical optical imaging reagents
12.5.7.1.2.2.Preclinical bioluminescent imaging reagents
12.5.7.1.2.2.1.Luciferins
12.5.7.1.2.2.2.Coelenterazne
12.5.7.1.2.2.3.Furimazine
12.5.7.1.2.3.Preclinical fluorescent imaging reagents
12.5.7.1.2.3.1.Green fluorescent proteins
12.5.7.1.2.3.2.Red fluorescent proteins
12.5.7.1.2.3.3.Infrared dyes
12.5.7.1.2.4.Preclinical nuclear imaging reagents
12.5.7.1.2.4.1.Preclinical pet tracers
12.5.7.1.2.4.2.Preclinical spect probes
12.5.7.1.2.5.Preclinical MRI contrast agents
12.5.7.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.7.1.2.5.2.Iron-based preclinical contrast agents
12.5.7.1.2.5.3.Manganese-based preclinical contrast agents
12.5.7.1.2.6.Preclinical ultrasound contrast agents
12.5.7.1.2.7.Preclinical CT contrast agents
12.5.7.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.7.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.7.1.2.7.3.Gold nanoparticles
12.5.7.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.7.1.3.Software
12.5.7.2.Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1.Oncology
12.5.7.2.2.Cardiology
12.5.7.2.3.Neurology
12.5.7.2.4.Infectious diseases
12.5.7.2.5.Immunology and inflammation
12.5.7.2.6.Other Applications
12.5.7.3.Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1.Pharmaceutical and Biotechnology companies
12.5.7.3.2.Academic and Research Centers
12.5.7.3.3.Imaging centers
12.5.7.3.4.Other end users
12.5.7.4.Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.Belgium
12.5.7.4.2.The Netherlands
12.5.7.4.3.Luxembourg
12.5.8.Rest of Europe
12.5.8.1.Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.8.1.1.Imaging systems
12.5.8.1.1.1.Optical imaging systems
12.5.8.1.1.1.1.Bioluminescence imaging systems
12.5.8.1.1.1.2.Fluorescence imaging systems
12.5.8.1.1.1.3.Other optical imaging systems
12.5.8.1.1.2.Nuclear imaging systems
12.5.8.1.1.2.1.micro-pet imaging systems
12.5.8.1.1.2.2.Micro-spect imaging systems
12.5.8.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
12.5.8.1.1.3.Micro-MRI systems
12.5.8.1.1.4.Micro-ultrasound systems
12.5.8.1.1.5.Micro-ct systems
12.5.8.1.1.6.Photoacoustic imaging systems
12.5.8.1.1.7.Magnetic particle imaging (mpi) systems
12.5.8.1.2.Reagents
12.5.8.1.2.1.Preclinical optical imaging reagents
12.5.8.1.2.2.Preclinical bioluminescent imaging reagents
12.5.8.1.2.2.1.Luciferins
12.5.8.1.2.2.2.Coelenterazne
12.5.8.1.2.2.3.Furimazine
12.5.8.1.2.3.Preclinical fluorescent imaging reagents
12.5.8.1.2.3.1.Green fluorescent proteins
12.5.8.1.2.3.2.Red fluorescent proteins
12.5.8.1.2.3.3.Infrared dyes
12.5.8.1.2.4.Preclinical nuclear imaging reagents
12.5.8.1.2.4.1.Preclinical pet tracers
12.5.8.1.2.4.2.Preclinical spect probes
12.5.8.1.2.5.Preclinical MRI contrast agents
12.5.8.1.2.5.1.Gadolinium-based preclinical contrast agents
12.5.8.1.2.5.2.Iron-based preclinical contrast agents
12.5.8.1.2.5.3.Manganese-based preclinical contrast agents
12.5.8.1.2.6.Preclinical ultrasound contrast agents
12.5.8.1.2.7.Preclinical CT contrast agents
12.5.8.1.2.7.1.Iodine-based preclinical ct contrast agents
12.5.8.1.2.7.2.Barium-based preclinical ct contrast agents
12.5.8.1.2.7.3.Gold nanoparticles
12.5.8.1.2.7.4.Gastrografin-based preclinical ct contrast agents
12.5.8.1.3.Software
12.5.8.2.Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.2.1.Oncology
12.5.8.2.2.Cardiology
12.5.8.2.3.Neurology
12.5.8.2.4.Infectious diseases
12.5.8.2.5.Immunology and inflammation
12.5.8.2.6.Other Applications
12.5.8.3.Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
12.5.8.3.1.Pharmaceutical and Biotechnology companies
12.5.8.3.2.Academic and Research Centers
12.5.8.3.3.Imaging centers
12.5.8.3.4.Other end users
12.6.Key Segment for Channeling Investments
12.6.1.By Country
12.6.2.By Product Type
12.6.3.By Application
12.6.4.By End User
13.Asia Pacific Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
13.1.Overview
13.1.1.Asia Pacific Preclinical Imaging Market Revenue (US$ Mn)
13.2.Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.2.1.Imaging systems
13.2.1.1.Optical imaging systems
13.2.1.1.1.Bioluminescence imaging systems
13.2.1.1.2.Fluorescence imaging systems
13.2.1.1.3.Other optical imaging systems
13.2.1.2.Nuclear imaging systems
13.2.1.2.1.micro-pet imaging systems
13.2.1.2.2.Micro-spect imaging systems
13.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.2.1.3.Micro-MRI systems
13.2.1.4.Micro-ultrasound systems
13.2.1.5.Micro-ct systems
13.2.1.6.Photoacoustic imaging systems
13.2.1.7.Magnetic particle imaging (mpi) systems
13.2.2.Reagents
13.2.2.1.Preclinical optical imaging reagents
13.2.2.2.Preclinical bioluminescent imaging reagents
13.2.2.2.1.Luciferins
13.2.2.2.2.Coelenterazne
13.2.2.2.3.Furimazine
13.2.2.3.Preclinical fluorescent imaging reagents
13.2.2.3.1.Green fluorescent proteins
13.2.2.3.2.Red fluorescent proteins
13.2.2.3.3.Infrared dyes
13.2.2.4.Preclinical nuclear imaging reagents
13.2.2.4.1.Preclinical pet tracers
13.2.2.4.2.Preclinical spect probes
13.2.2.5.Preclinical MRI contrast agents
13.2.2.5.1.Gadolinium-based preclinical contrast agents
13.2.2.5.2.Iron-based preclinical contrast agents
13.2.2.5.3.Manganese-based preclinical contrast agents
13.2.2.6.Preclinical ultrasound contrast agents
13.2.2.7.Preclinical CT contrast agents
13.2.2.7.1.Iodine-based preclinical ct contrast agents
13.2.2.7.2.Barium-based preclinical ct contrast agents
13.2.2.7.3.Gold nanoparticles
13.2.2.7.4.Gastrografin-based preclinical ct contrast agents
13.2.3.Software
13.3.Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1.Oncology
13.3.2.Cardiology
13.3.3.Neurology
13.3.4.Infectious diseases
13.3.5.Immunology and inflammation
13.3.6.Other Applications
13.4.Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.4.1.Pharmaceutical and Biotechnology companies
13.4.2.Academic and Research Centers
13.4.3.Imaging centers
13.4.4.Other end users
13.5.Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1.China
13.5.1.1.China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.1.1.1.Imaging systems
13.5.1.1.1.1.Optical imaging systems
13.5.1.1.1.1.1.Bioluminescence imaging systems
13.5.1.1.1.1.2.Fluorescence imaging systems
13.5.1.1.1.1.3.Other optical imaging systems
13.5.1.1.1.2.Nuclear imaging systems
13.5.1.1.1.2.1.micro-pet imaging systems
13.5.1.1.1.2.2.Micro-spect imaging systems
13.5.1.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.1.1.1.3.Micro-MRI systems
13.5.1.1.1.4.Micro-ultrasound systems
13.5.1.1.1.5.Micro-ct systems
13.5.1.1.1.6.Photoacoustic imaging systems
13.5.1.1.1.7.Magnetic particle imaging (mpi) systems
13.5.1.1.2.Reagents
13.5.1.1.2.1.Preclinical optical imaging reagents
13.5.1.1.2.2.Preclinical bioluminescent imaging reagents
13.5.1.1.2.2.1.Luciferins
13.5.1.1.2.2.2.Coelenterazne
13.5.1.1.2.2.3.Furimazine
13.5.1.1.2.3.Preclinical fluorescent imaging reagents
13.5.1.1.2.3.1.Green fluorescent proteins
13.5.1.1.2.3.2.Red fluorescent proteins
13.5.1.1.2.3.3.Infrared dyes
13.5.1.1.2.4.Preclinical nuclear imaging reagents
13.5.1.1.2.4.1.Preclinical pet tracers
13.5.1.1.2.4.2.Preclinical spect probes
13.5.1.1.2.5.Preclinical MRI contrast agents
13.5.1.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.1.1.2.5.2.Iron-based preclinical contrast agents
13.5.1.1.2.5.3.Manganese-based preclinical contrast agents
13.5.1.1.2.6.Preclinical ultrasound contrast agents
13.5.1.1.2.7.Preclinical CT contrast agents
13.5.1.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.1.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.1.1.2.7.3.Gold nanoparticles
13.5.1.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.1.1.3.Software
13.5.1.2.China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.2.1.Oncology
13.5.1.2.2.Cardiology
13.5.1.2.3.Neurology
13.5.1.2.4.Infectious diseases
13.5.1.2.5.Immunology and inflammation
13.5.1.2.6.Other Applications
13.5.1.3.China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1.3.1.Pharmaceutical and Biotechnology companies
13.5.1.3.2.Academic and Research Centers
13.5.1.3.3.Imaging centers
13.5.1.3.4.Other end users
13.5.2.Japan
13.5.2.1.Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.2.1.1.Imaging systems
13.5.2.1.1.1.Optical imaging systems
13.5.2.1.1.1.1.Bioluminescence imaging systems
13.5.2.1.1.1.2.Fluorescence imaging systems
13.5.2.1.1.1.3.Other optical imaging systems
13.5.2.1.1.2.Nuclear imaging systems
13.5.2.1.1.2.1.micro-pet imaging systems
13.5.2.1.1.2.2.Micro-spect imaging systems
13.5.2.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.2.1.1.3.Micro-MRI systems
13.5.2.1.1.4.Micro-ultrasound systems
13.5.2.1.1.5.Micro-ct systems
13.5.2.1.1.6.Photoacoustic imaging systems
13.5.2.1.1.7.Magnetic particle imaging (mpi) systems
13.5.2.1.2.Reagents
13.5.2.1.2.1.Preclinical optical imaging reagents
13.5.2.1.2.2.Preclinical bioluminescent imaging reagents
13.5.2.1.2.2.1.Luciferins
13.5.2.1.2.2.2.Coelenterazne
13.5.2.1.2.2.3.Furimazine
13.5.2.1.2.3.Preclinical fluorescent imaging reagents
13.5.2.1.2.3.1.Green fluorescent proteins
13.5.2.1.2.3.2.Red fluorescent proteins
13.5.2.1.2.3.3.Infrared dyes
13.5.2.1.2.4.Preclinical nuclear imaging reagents
13.5.2.1.2.4.1.Preclinical pet tracers
13.5.2.1.2.4.2.Preclinical spect probes
13.5.2.1.2.5.Preclinical MRI contrast agents
13.5.2.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.2.1.2.5.2.Iron-based preclinical contrast agents
13.5.2.1.2.5.3.Manganese-based preclinical contrast agents
13.5.2.1.2.6.Preclinical ultrasound contrast agents
13.5.2.1.2.7.Preclinical CT contrast agents
13.5.2.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.2.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.2.1.2.7.3.Gold nanoparticles
13.5.2.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.2.1.3.Software
13.5.2.2.Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.2.1.Oncology
13.5.2.2.2.Cardiology
13.5.2.2.3.Neurology
13.5.2.2.4.Infectious diseases
13.5.2.2.5.Immunology and inflammation
13.5.2.2.6.Other Applications
13.5.2.3.Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.2.3.1.Pharmaceutical and Biotechnology companies
13.5.2.3.2.Academic and Research Centers
13.5.2.3.3.Imaging centers
13.5.2.3.4.Other end users
13.5.3.India
13.5.3.1.India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.3.1.1.Imaging systems
13.5.3.1.1.1.Optical imaging systems
13.5.3.1.1.1.1.Bioluminescence imaging systems
13.5.3.1.1.1.2.Fluorescence imaging systems
13.5.3.1.1.1.3.Other optical imaging systems
13.5.3.1.1.2.Nuclear imaging systems
13.5.3.1.1.2.1.micro-pet imaging systems
13.5.3.1.1.2.2.Micro-spect imaging systems
13.5.3.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.3.1.1.3.Micro-MRI systems
13.5.3.1.1.4.Micro-ultrasound systems
13.5.3.1.1.5.Micro-ct systems
13.5.3.1.1.6.Photoacoustic imaging systems
13.5.3.1.1.7.Magnetic particle imaging (mpi) systems
13.5.3.1.2.Reagents
13.5.3.1.2.1.Preclinical optical imaging reagents
13.5.3.1.2.2.Preclinical bioluminescent imaging reagents
13.5.3.1.2.2.1.Luciferins
13.5.3.1.2.2.2.Coelenterazne
13.5.3.1.2.2.3.Furimazine
13.5.3.1.2.3.Preclinical fluorescent imaging reagents
13.5.3.1.2.3.1.Green fluorescent proteins
13.5.3.1.2.3.2.Red fluorescent proteins
13.5.3.1.2.3.3.Infrared dyes
13.5.3.1.2.4.Preclinical nuclear imaging reagents
13.5.3.1.2.4.1.Preclinical pet tracers
13.5.3.1.2.4.2.Preclinical spect probes
13.5.3.1.2.5.Preclinical MRI contrast agents
13.5.3.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.3.1.2.5.2.Iron-based preclinical contrast agents
13.5.3.1.2.5.3.Manganese-based preclinical contrast agents
13.5.3.1.2.6.Preclinical ultrasound contrast agents
13.5.3.1.2.7.Preclinical CT contrast agents
13.5.3.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.3.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.3.1.2.7.3.Gold nanoparticles
13.5.3.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.3.1.3.Software
13.5.3.2.India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1.Oncology
13.5.3.2.2.Cardiology
13.5.3.2.3.Neurology
13.5.3.2.4.Infectious diseases
13.5.3.2.5.Immunology and inflammation
13.5.3.2.6.Other Applications
13.5.3.3.India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.3.3.1.Pharmaceutical and Biotechnology companies
13.5.3.3.2.Academic and Research Centers
13.5.3.3.3.Imaging centers
13.5.3.3.4.Other end users
13.5.4.New Zealand
13.5.4.1.New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.4.1.1.Imaging systems
13.5.4.1.1.1.Optical imaging systems
13.5.4.1.1.1.1.Bioluminescence imaging systems
13.5.4.1.1.1.2.Fluorescence imaging systems
13.5.4.1.1.1.3.Other optical imaging systems
13.5.4.1.1.2.Nuclear imaging systems
13.5.4.1.1.2.1.micro-pet imaging systems
13.5.4.1.1.2.2.Micro-spect imaging systems
13.5.4.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.4.1.1.3.Micro-MRI systems
13.5.4.1.1.4.Micro-ultrasound systems
13.5.4.1.1.5.Micro-ct systems
13.5.4.1.1.6.Photoacoustic imaging systems
13.5.4.1.1.7.Magnetic particle imaging (mpi) systems
13.5.4.1.2.Reagents
13.5.4.1.2.1.Preclinical optical imaging reagents
13.5.4.1.2.2.Preclinical bioluminescent imaging reagents
13.5.4.1.2.2.1.Luciferins
13.5.4.1.2.2.2.Coelenterazne
13.5.4.1.2.2.3.Furimazine
13.5.4.1.2.3.Preclinical fluorescent imaging reagents
13.5.4.1.2.3.1.Green fluorescent proteins
13.5.4.1.2.3.2.Red fluorescent proteins
13.5.4.1.2.3.3.Infrared dyes
13.5.4.1.2.4.Preclinical nuclear imaging reagents
13.5.4.1.2.4.1.Preclinical pet tracers
13.5.4.1.2.4.2.Preclinical spect probes
13.5.4.1.2.5.Preclinical MRI contrast agents
13.5.4.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.4.1.2.5.2.Iron-based preclinical contrast agents
13.5.4.1.2.5.3.Manganese-based preclinical contrast agents
13.5.4.1.2.6.Preclinical ultrasound contrast agents
13.5.4.1.2.7.Preclinical CT contrast agents
13.5.4.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.4.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.4.1.2.7.3.Gold nanoparticles
13.5.4.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.4.1.3.Software
13.5.4.2.New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.2.1.Oncology
13.5.4.2.2.Cardiology
13.5.4.2.3.Neurology
13.5.4.2.4.Infectious diseases
13.5.4.2.5.Immunology and inflammation
13.5.4.2.6.Other Applications
13.5.4.3.New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1.Pharmaceutical and Biotechnology companies
13.5.4.3.2.Academic and Research Centers
13.5.4.3.3.Imaging centers
13.5.4.3.4.Other end users
13.5.5.Australia
13.5.5.1.Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.5.1.1.Imaging systems
13.5.5.1.1.1.Optical imaging systems
13.5.5.1.1.1.1.Bioluminescence imaging systems
13.5.5.1.1.1.2.Fluorescence imaging systems
13.5.5.1.1.1.3.Other optical imaging systems
13.5.5.1.1.2.Nuclear imaging systems
13.5.5.1.1.2.1.micro-pet imaging systems
13.5.5.1.1.2.2.Micro-spect imaging systems
13.5.5.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.5.1.1.3.Micro-MRI systems
13.5.5.1.1.4.Micro-ultrasound systems
13.5.5.1.1.5.Micro-ct systems
13.5.5.1.1.6.Photoacoustic imaging systems
13.5.5.1.1.7.Magnetic particle imaging (mpi) systems
13.5.5.1.2.Reagents
13.5.5.1.2.1.Preclinical optical imaging reagents
13.5.5.1.2.2.Preclinical bioluminescent imaging reagents
13.5.5.1.2.2.1.Luciferins
13.5.5.1.2.2.2.Coelenterazne
13.5.5.1.2.2.3.Furimazine
13.5.5.1.2.3.Preclinical fluorescent imaging reagents
13.5.5.1.2.3.1.Green fluorescent proteins
13.5.5.1.2.3.2.Red fluorescent proteins
13.5.5.1.2.3.3.Infrared dyes
13.5.5.1.2.4.Preclinical nuclear imaging reagents
13.5.5.1.2.4.1.Preclinical pet tracers
13.5.5.1.2.4.2.Preclinical spect probes
13.5.5.1.2.5.Preclinical MRI contrast agents
13.5.5.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.5.1.2.5.2.Iron-based preclinical contrast agents
13.5.5.1.2.5.3.Manganese-based preclinical contrast agents
13.5.5.1.2.6.Preclinical ultrasound contrast agents
13.5.5.1.2.7.Preclinical CT contrast agents
13.5.5.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.5.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.5.1.2.7.3.Gold nanoparticles
13.5.5.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.5.1.3.Software
13.5.5.2.Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1.Oncology
13.5.5.2.2.Cardiology
13.5.5.2.3.Neurology
13.5.5.2.4.Infectious diseases
13.5.5.2.5.Immunology and inflammation
13.5.5.2.6.Other Applications
13.5.5.3.Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1.Pharmaceutical and Biotechnology companies
13.5.5.3.2.Academic and Research Centers
13.5.5.3.3.Imaging centers
13.5.5.3.4.Other end users
13.5.6.South Korea
13.5.6.1.South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.6.1.1.Imaging systems
13.5.6.1.1.1.Optical imaging systems
13.5.6.1.1.1.1.Bioluminescence imaging systems
13.5.6.1.1.1.2.Fluorescence imaging systems
13.5.6.1.1.1.3.Other optical imaging systems
13.5.6.1.1.2.Nuclear imaging systems
13.5.6.1.1.2.1.micro-pet imaging systems
13.5.6.1.1.2.2.Micro-spect imaging systems
13.5.6.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.6.1.1.3.Micro-MRI systems
13.5.6.1.1.4.Micro-ultrasound systems
13.5.6.1.1.5.Micro-ct systems
13.5.6.1.1.6.Photoacoustic imaging systems
13.5.6.1.1.7.Magnetic particle imaging (mpi) systems
13.5.6.1.2.Reagents
13.5.6.1.2.1.Preclinical optical imaging reagents
13.5.6.1.2.2.Preclinical bioluminescent imaging reagents
13.5.6.1.2.2.1.Luciferins
13.5.6.1.2.2.2.Coelenterazne
13.5.6.1.2.2.3.Furimazine
13.5.6.1.2.3.Preclinical fluorescent imaging reagents
13.5.6.1.2.3.1.Green fluorescent proteins
13.5.6.1.2.3.2.Red fluorescent proteins
13.5.6.1.2.3.3.Infrared dyes
13.5.6.1.2.4.Preclinical nuclear imaging reagents
13.5.6.1.2.4.1.Preclinical pet tracers
13.5.6.1.2.4.2.Preclinical spect probes
13.5.6.1.2.5.Preclinical MRI contrast agents
13.5.6.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.6.1.2.5.2.Iron-based preclinical contrast agents
13.5.6.1.2.5.3.Manganese-based preclinical contrast agents
13.5.6.1.2.6.Preclinical ultrasound contrast agents
13.5.6.1.2.7.Preclinical CT contrast agents
13.5.6.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.6.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.6.1.2.7.3.Gold nanoparticles
13.5.6.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.6.1.3.Software
13.5.6.2.South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.2.1.Oncology
13.5.6.2.2.Cardiology
13.5.6.2.3.Neurology
13.5.6.2.4.Infectious diseases
13.5.6.2.5.Immunology and inflammation
13.5.6.2.6.Other Applications
13.5.6.3.South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.6.3.1.Pharmaceutical and Biotechnology companies
13.5.6.3.2.Academic and Research Centers
13.5.6.3.3.Imaging centers
13.5.6.3.4.Other end users
13.5.7.Southeast Asia
13.5.7.1.Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.7.1.1.Imaging systems
13.5.7.1.1.1.Optical imaging systems
13.5.7.1.1.1.1.Bioluminescence imaging systems
13.5.7.1.1.1.2.Fluorescence imaging systems
13.5.7.1.1.1.3.Other optical imaging systems
13.5.7.1.1.2.Nuclear imaging systems
13.5.7.1.1.2.1.micro-pet imaging systems
13.5.7.1.1.2.2.Micro-spect imaging systems
13.5.7.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.7.1.1.3.Micro-MRI systems
13.5.7.1.1.4.Micro-ultrasound systems
13.5.7.1.1.5.Micro-ct systems
13.5.7.1.1.6.Photoacoustic imaging systems
13.5.7.1.1.7.Magnetic particle imaging (mpi) systems
13.5.7.1.2.Reagents
13.5.7.1.2.1.Preclinical optical imaging reagents
13.5.7.1.2.2.Preclinical bioluminescent imaging reagents
13.5.7.1.2.2.1.Luciferins
13.5.7.1.2.2.2.Coelenterazne
13.5.7.1.2.2.3.Furimazine
13.5.7.1.2.3.Preclinical fluorescent imaging reagents
13.5.7.1.2.3.1.Green fluorescent proteins
13.5.7.1.2.3.2.Red fluorescent proteins
13.5.7.1.2.3.3.Infrared dyes
13.5.7.1.2.4.Preclinical nuclear imaging reagents
13.5.7.1.2.4.1.Preclinical pet tracers
13.5.7.1.2.4.2.Preclinical spect probes
13.5.7.1.2.5.Preclinical MRI contrast agents
13.5.7.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.7.1.2.5.2.Iron-based preclinical contrast agents
13.5.7.1.2.5.3.Manganese-based preclinical contrast agents
13.5.7.1.2.6.Preclinical ultrasound contrast agents
13.5.7.1.2.7.Preclinical CT contrast agents
13.5.7.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.7.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.7.1.2.7.3.Gold nanoparticles
13.5.7.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.7.1.3.Software
13.5.7.2.Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1.Oncology
13.5.7.2.2.Cardiology
13.5.7.2.3.Neurology
13.5.7.2.4.Infectious diseases
13.5.7.2.5.Immunology and inflammation
13.5.7.2.6.Other Applications
13.5.7.3.Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1.Pharmaceutical and Biotechnology companies
13.5.7.3.2.Academic and Research Centers
13.5.7.3.3.Imaging centers
13.5.7.3.4.Other end users
13.5.7.4.Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.Indonesia
13.5.7.4.2.Thailand
13.5.7.4.3.Malaysia
13.5.7.4.4.Singapore
13.5.7.4.5.Rest of Southeast Asia
13.5.8.Rest of Asia Pacific
13.5.8.1.Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.8.1.1.Imaging systems
13.5.8.1.1.1.Optical imaging systems
13.5.8.1.1.1.1.Bioluminescence imaging systems
13.5.8.1.1.1.2.Fluorescence imaging systems
13.5.8.1.1.1.3.Other optical imaging systems
13.5.8.1.1.2.Nuclear imaging systems
13.5.8.1.1.2.1.micro-pet imaging systems
13.5.8.1.1.2.2.Micro-spect imaging systems
13.5.8.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
13.5.8.1.1.3.Micro-MRI systems
13.5.8.1.1.4.Micro-ultrasound systems
13.5.8.1.1.5.Micro-ct systems
13.5.8.1.1.6.Photoacoustic imaging systems
13.5.8.1.1.7.Magnetic particle imaging (mpi) systems
13.5.8.1.2.Reagents
13.5.8.1.2.1.Preclinical optical imaging reagents
13.5.8.1.2.2.Preclinical bioluminescent imaging reagents
13.5.8.1.2.2.1.Luciferins
13.5.8.1.2.2.2.Coelenterazne
13.5.8.1.2.2.3.Furimazine
13.5.8.1.2.3.Preclinical fluorescent imaging reagents
13.5.8.1.2.3.1.Green fluorescent proteins
13.5.8.1.2.3.2.Red fluorescent proteins
13.5.8.1.2.3.3.Infrared dyes
13.5.8.1.2.4.Preclinical nuclear imaging reagents
13.5.8.1.2.4.1.Preclinical pet tracers
13.5.8.1.2.4.2.Preclinical spect probes
13.5.8.1.2.5.Preclinical MRI contrast agents
13.5.8.1.2.5.1.Gadolinium-based preclinical contrast agents
13.5.8.1.2.5.2.Iron-based preclinical contrast agents
13.5.8.1.2.5.3.Manganese-based preclinical contrast agents
13.5.8.1.2.6.Preclinical ultrasound contrast agents
13.5.8.1.2.7.Preclinical CT contrast agents
13.5.8.1.2.7.1.Iodine-based preclinical ct contrast agents
13.5.8.1.2.7.2.Barium-based preclinical ct contrast agents
13.5.8.1.2.7.3.Gold nanoparticles
13.5.8.1.2.7.4.Gastrografin-based preclinical ct contrast agents
13.5.8.1.3.Software
13.5.8.2.Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1.Oncology
13.5.8.2.2.Cardiology
13.5.8.2.3.Neurology
13.5.8.2.4.Infectious diseases
13.5.8.2.5.Immunology and inflammation
13.5.8.2.6.Other Applications
13.5.8.3.Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1.Pharmaceutical and Biotechnology companies
13.5.8.3.2.Academic and Research Centers
13.5.8.3.3.Imaging centers
13.5.8.3.4.Other end users
13.6.Key Segment for Channeling Investments
13.6.1.By Country
13.6.2.By Product Type
13.6.3.By Application
13.6.4.By End User
14.Middle East and Africa Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.1.1.Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn)
14.2.Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.2.1.Imaging systems
14.2.1.1.Optical imaging systems
14.2.1.1.1.Bioluminescence imaging systems
14.2.1.1.2.Fluorescence imaging systems
14.2.1.1.3.Other optical imaging systems
14.2.1.2.Nuclear imaging systems
14.2.1.2.1.micro-pet imaging systems
14.2.1.2.2.Micro-spect imaging systems
14.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.2.1.3.Micro-MRI systems
14.2.1.4.Micro-ultrasound systems
14.2.1.5.Micro-ct systems
14.2.1.6.Photoacoustic imaging systems
14.2.1.7.Magnetic particle imaging (mpi) systems
14.2.2.Reagents
14.2.2.1.Preclinical optical imaging reagents
14.2.2.2.Preclinical bioluminescent imaging reagents
14.2.2.2.1.Luciferins
14.2.2.2.2.Coelenterazne
14.2.2.2.3.Furimazine
14.2.2.3.Preclinical fluorescent imaging reagents
14.2.2.3.1.Green fluorescent proteins
14.2.2.3.2.Red fluorescent proteins
14.2.2.3.3.Infrared dyes
14.2.2.4.Preclinical nuclear imaging reagents
14.2.2.4.1.Preclinical pet tracers
14.2.2.4.2.Preclinical spect probes
14.2.2.5.Preclinical MRI contrast agents
14.2.2.5.1.Gadolinium-based preclinical contrast agents
14.2.2.5.2.Iron-based preclinical contrast agents
14.2.2.5.3.Manganese-based preclinical contrast agents
14.2.2.6.Preclinical ultrasound contrast agents
14.2.2.7.Preclinical CT contrast agents
14.2.2.7.1.Iodine-based preclinical ct contrast agents
14.2.2.7.2.Barium-based preclinical ct contrast agents
14.2.2.7.3.Gold nanoparticles
14.2.2.7.4.Gastrografin-based preclinical ct contrast agents
14.2.3.Software
14.3.Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1.Oncology
14.3.2.Cardiology
14.3.3.Neurology
14.3.4.Infectious diseases
14.3.5.Immunology and inflammation
14.3.6.Other Applications
14.4.Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1.Pharmaceutical and Biotechnology companies
14.4.2.Academic and Research Centers
14.4.3.Imaging centers
14.4.4.Other end users
14.5.Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1.Saudi Arabia
14.5.1.1.Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.1.1.1.Imaging systems
14.5.1.1.1.1.Optical imaging systems
14.5.1.1.1.1.1.Bioluminescence imaging systems
14.5.1.1.1.1.2.Fluorescence imaging systems
14.5.1.1.1.1.3.Other optical imaging systems
14.5.1.1.1.2.Nuclear imaging systems
14.5.1.1.1.2.1.micro-pet imaging systems
14.5.1.1.1.2.2.Micro-spect imaging systems
14.5.1.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.1.1.1.3.Micro-MRI systems
14.5.1.1.1.4.Micro-ultrasound systems
14.5.1.1.1.5.Micro-ct systems
14.5.1.1.1.6.Photoacoustic imaging systems
14.5.1.1.1.7.Magnetic particle imaging (mpi) systems
14.5.1.1.2.Reagents
14.5.1.1.2.1.Preclinical optical imaging reagents
14.5.1.1.2.2.Preclinical bioluminescent imaging reagents
14.5.1.1.2.2.1.Luciferins
14.5.1.1.2.2.2.Coelenterazne
14.5.1.1.2.2.3.Furimazine
14.5.1.1.2.3.Preclinical fluorescent imaging reagents
14.5.1.1.2.3.1.Green fluorescent proteins
14.5.1.1.2.3.2.Red fluorescent proteins
14.5.1.1.2.3.3.Infrared dyes
14.5.1.1.2.4.Preclinical nuclear imaging reagents
14.5.1.1.2.4.1.Preclinical pet tracers
14.5.1.1.2.4.2.Preclinical spect probes
14.5.1.1.2.5.Preclinical MRI contrast agents
14.5.1.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.1.1.2.5.2.Iron-based preclinical contrast agents
14.5.1.1.2.5.3.Manganese-based preclinical contrast agents
14.5.1.1.2.6.Preclinical ultrasound contrast agents
14.5.1.1.2.7.Preclinical CT contrast agents
14.5.1.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.1.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.1.1.2.7.3.Gold nanoparticles
14.5.1.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.1.1.3.Software
14.5.1.2.Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.2.1.Oncology
14.5.1.2.2.Cardiology
14.5.1.2.3.Neurology
14.5.1.2.4.Infectious diseases
14.5.1.2.5.Immunology and inflammation
14.5.1.2.6.Other Applications
14.5.1.3.Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1.Pharmaceutical and Biotechnology companies
14.5.1.3.2.Academic and Research Centers
14.5.1.3.3.Imaging centers
14.5.1.3.4.Other end users
14.5.2.UAE
14.5.2.1.UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.2.1.1.Imaging systems
14.5.2.1.1.1.Optical imaging systems
14.5.2.1.1.1.1.Bioluminescence imaging systems
14.5.2.1.1.1.2.Fluorescence imaging systems
14.5.2.1.1.1.3.Other optical imaging systems
14.5.2.1.1.2.Nuclear imaging systems
14.5.2.1.1.2.1.micro-pet imaging systems
14.5.2.1.1.2.2.Micro-spect imaging systems
14.5.2.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.2.1.1.3.Micro-MRI systems
14.5.2.1.1.4.Micro-ultrasound systems
14.5.2.1.1.5.Micro-ct systems
14.5.2.1.1.6.Photoacoustic imaging systems
14.5.2.1.1.7.Magnetic particle imaging (mpi) systems
14.5.2.1.2.Reagents
14.5.2.1.2.1.Preclinical optical imaging reagents
14.5.2.1.2.2.Preclinical bioluminescent imaging reagents
14.5.2.1.2.2.1.Luciferins
14.5.2.1.2.2.2.Coelenterazne
14.5.2.1.2.2.3.Furimazine
14.5.2.1.2.3.Preclinical fluorescent imaging reagents
14.5.2.1.2.3.1.Green fluorescent proteins
14.5.2.1.2.3.2.Red fluorescent proteins
14.5.2.1.2.3.3.Infrared dyes
14.5.2.1.2.4.Preclinical nuclear imaging reagents
14.5.2.1.2.4.1.Preclinical pet tracers
14.5.2.1.2.4.2.Preclinical spect probes
14.5.2.1.2.5.Preclinical MRI contrast agents
14.5.2.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.2.1.2.5.2.Iron-based preclinical contrast agents
14.5.2.1.2.5.3.Manganese-based preclinical contrast agents
14.5.2.1.2.6.Preclinical ultrasound contrast agents
14.5.2.1.2.7.Preclinical CT contrast agents
14.5.2.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.2.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.2.1.2.7.3.Gold nanoparticles
14.5.2.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.2.1.3.Software
14.5.2.2.UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.2.1.Oncology
14.5.2.2.2.Cardiology
14.5.2.2.3.Neurology
14.5.2.2.4.Infectious diseases
14.5.2.2.5.Immunology and inflammation
14.5.2.2.6.Other Applications
14.5.2.3.UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.2.3.1.Pharmaceutical and Biotechnology companies
14.5.2.3.2.Academic and Research Centers
14.5.2.3.3.Imaging centers
14.5.2.3.4.Other end users
14.5.3.Egypt
14.5.3.1.Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.3.1.1.Imaging systems
14.5.3.1.1.1.Optical imaging systems
14.5.3.1.1.1.1.Bioluminescence imaging systems
14.5.3.1.1.1.2.Fluorescence imaging systems
14.5.3.1.1.1.3.Other optical imaging systems
14.5.3.1.1.2.Nuclear imaging systems
14.5.3.1.1.2.1.micro-pet imaging systems
14.5.3.1.1.2.2.Micro-spect imaging systems
14.5.3.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.3.1.1.3.Micro-MRI systems
14.5.3.1.1.4.Micro-ultrasound systems
14.5.3.1.1.5.Micro-ct systems
14.5.3.1.1.6.Photoacoustic imaging systems
14.5.3.1.1.7.Magnetic particle imaging (mpi) systems
14.5.3.1.2.Reagents
14.5.3.1.2.1.Preclinical optical imaging reagents
14.5.3.1.2.2.Preclinical bioluminescent imaging reagents
14.5.3.1.2.2.1.Luciferins
14.5.3.1.2.2.2.Coelenterazne
14.5.3.1.2.2.3.Furimazine
14.5.3.1.2.3.Preclinical fluorescent imaging reagents
14.5.3.1.2.3.1.Green fluorescent proteins
14.5.3.1.2.3.2.Red fluorescent proteins
14.5.3.1.2.3.3.Infrared dyes
14.5.3.1.2.4.Preclinical nuclear imaging reagents
14.5.3.1.2.4.1.Preclinical pet tracers
14.5.3.1.2.4.2.Preclinical spect probes
14.5.3.1.2.5.Preclinical MRI contrast agents
14.5.3.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.3.1.2.5.2.Iron-based preclinical contrast agents
14.5.3.1.2.5.3.Manganese-based preclinical contrast agents
14.5.3.1.2.6.Preclinical ultrasound contrast agents
14.5.3.1.2.7.Preclinical CT contrast agents
14.5.3.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.3.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.3.1.2.7.3.Gold nanoparticles
14.5.3.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.3.1.3.Software
14.5.3.2.Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1.Oncology
14.5.3.2.2.Cardiology
14.5.3.2.3.Neurology
14.5.3.2.4.Infectious diseases
14.5.3.2.5.Immunology and inflammation
14.5.3.2.6.Other Applications
14.5.3.3.Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.3.3.1.Pharmaceutical and Biotechnology companies
14.5.3.3.2.Academic and Research Centers
14.5.3.3.3.Imaging centers
14.5.3.3.4.Other end users
14.5.4.Kuwait
14.5.4.1.Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.4.1.1.Imaging systems
14.5.4.1.1.1.Optical imaging systems
14.5.4.1.1.1.1.Bioluminescence imaging systems
14.5.4.1.1.1.2.Fluorescence imaging systems
14.5.4.1.1.1.3.Other optical imaging systems
14.5.4.1.1.2.Nuclear imaging systems
14.5.4.1.1.2.1.micro-pet imaging systems
14.5.4.1.1.2.2.Micro-spect imaging systems
14.5.4.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.4.1.1.3.Micro-MRI systems
14.5.4.1.1.4.Micro-ultrasound systems
14.5.4.1.1.5.Micro-ct systems
14.5.4.1.1.6.Photoacoustic imaging systems
14.5.4.1.1.7.Magnetic particle imaging (mpi) systems
14.5.4.1.2.Reagents
14.5.4.1.2.1.Preclinical optical imaging reagents
14.5.4.1.2.2.Preclinical bioluminescent imaging reagents
14.5.4.1.2.2.1.Luciferins
14.5.4.1.2.2.2.Coelenterazne
14.5.4.1.2.2.3.Furimazine
14.5.4.1.2.3.Preclinical fluorescent imaging reagents
14.5.4.1.2.3.1.Green fluorescent proteins
14.5.4.1.2.3.2.Red fluorescent proteins
14.5.4.1.2.3.3.Infrared dyes
14.5.4.1.2.4.Preclinical nuclear imaging reagents
14.5.4.1.2.4.1.Preclinical pet tracers
14.5.4.1.2.4.2.Preclinical spect probes
14.5.4.1.2.5.Preclinical MRI contrast agents
14.5.4.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.4.1.2.5.2.Iron-based preclinical contrast agents
14.5.4.1.2.5.3.Manganese-based preclinical contrast agents
14.5.4.1.2.6.Preclinical ultrasound contrast agents
14.5.4.1.2.7.Preclinical CT contrast agents
14.5.4.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.4.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.4.1.2.7.3.Gold nanoparticles
14.5.4.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.4.1.3.Software
14.5.4.2.Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1.Oncology
14.5.4.2.2.Cardiology
14.5.4.2.3.Neurology
14.5.4.2.4.Infectious diseases
14.5.4.2.5.Immunology and inflammation
14.5.4.2.6.Other Applications
14.5.4.3.Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.4.3.1.Pharmaceutical and Biotechnology companies
14.5.4.3.2.Academic and Research Centers
14.5.4.3.3.Imaging centers
14.5.4.3.4.Other end users
14.5.5.South Africa
14.5.5.1.South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.5.1.1.Imaging systems
14.5.5.1.1.1.Optical imaging systems
14.5.5.1.1.1.1.Bioluminescence imaging systems
14.5.5.1.1.1.2.Fluorescence imaging systems
14.5.5.1.1.1.3.Other optical imaging systems
14.5.5.1.1.2.Nuclear imaging systems
14.5.5.1.1.2.1.micro-pet imaging systems
14.5.5.1.1.2.2.Micro-spect imaging systems
14.5.5.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.5.1.1.3.Micro-MRI systems
14.5.5.1.1.4.Micro-ultrasound systems
14.5.5.1.1.5.Micro-ct systems
14.5.5.1.1.6.Photoacoustic imaging systems
14.5.5.1.1.7.Magnetic particle imaging (mpi) systems
14.5.5.1.2.Reagents
14.5.5.1.2.1.Preclinical optical imaging reagents
14.5.5.1.2.2.Preclinical bioluminescent imaging reagents
14.5.5.1.2.2.1.Luciferins
14.5.5.1.2.2.2.Coelenterazne
14.5.5.1.2.2.3.Furimazine
14.5.5.1.2.3.Preclinical fluorescent imaging reagents
14.5.5.1.2.3.1.Green fluorescent proteins
14.5.5.1.2.3.2.Red fluorescent proteins
14.5.5.1.2.3.3.Infrared dyes
14.5.5.1.2.4.Preclinical nuclear imaging reagents
14.5.5.1.2.4.1.Preclinical pet tracers
14.5.5.1.2.4.2.Preclinical spect probes
14.5.5.1.2.5.Preclinical MRI contrast agents
14.5.5.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.5.1.2.5.2.Iron-based preclinical contrast agents
14.5.5.1.2.5.3.Manganese-based preclinical contrast agents
14.5.5.1.2.6.Preclinical ultrasound contrast agents
14.5.5.1.2.7.Preclinical CT contrast agents
14.5.5.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.5.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.5.1.2.7.3.Gold nanoparticles
14.5.5.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.5.1.3.Software
14.5.5.2.South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.2.1.Oncology
14.5.5.2.2.Cardiology
14.5.5.2.3.Neurology
14.5.5.2.4.Infectious diseases
14.5.5.2.5.Immunology and inflammation
14.5.5.2.6.Other Applications
14.5.5.3.South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.5.3.1.Pharmaceutical and Biotechnology companies
14.5.5.3.2.Academic and Research Centers
14.5.5.3.3.Imaging centers
14.5.5.3.4.Other end users
14.5.6.Rest of Middle East & Africa
14.5.6.1.Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.6.1.1.Imaging systems
14.5.6.1.1.1.Optical imaging systems
14.5.6.1.1.1.1.Bioluminescence imaging systems
14.5.6.1.1.1.2.Fluorescence imaging systems
14.5.6.1.1.1.3.Other optical imaging systems
14.5.6.1.1.2.Nuclear imaging systems
14.5.6.1.1.2.1.micro-pet imaging systems
14.5.6.1.1.2.2.Micro-spect imaging systems
14.5.6.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
14.5.6.1.1.3.Micro-MRI systems
14.5.6.1.1.4.Micro-ultrasound systems
14.5.6.1.1.5.Micro-ct systems
14.5.6.1.1.6.Photoacoustic imaging systems
14.5.6.1.1.7.Magnetic particle imaging (mpi) systems
14.5.6.1.2.Reagents
14.5.6.1.2.1.Preclinical optical imaging reagents
14.5.6.1.2.2.Preclinical bioluminescent imaging reagents
14.5.6.1.2.2.1.Luciferins
14.5.6.1.2.2.2.Coelenterazne
14.5.6.1.2.2.3.Furimazine
14.5.6.1.2.3.Preclinical fluorescent imaging reagents
14.5.6.1.2.3.1.Green fluorescent proteins
14.5.6.1.2.3.2.Red fluorescent proteins
14.5.6.1.2.3.3.Infrared dyes
14.5.6.1.2.4.Preclinical nuclear imaging reagents
14.5.6.1.2.4.1.Preclinical pet tracers
14.5.6.1.2.4.2.Preclinical spect probes
14.5.6.1.2.5.Preclinical MRI contrast agents
14.5.6.1.2.5.1.Gadolinium-based preclinical contrast agents
14.5.6.1.2.5.2.Iron-based preclinical contrast agents
14.5.6.1.2.5.3.Manganese-based preclinical contrast agents
14.5.6.1.2.6.Preclinical ultrasound contrast agents
14.5.6.1.2.7.Preclinical CT contrast agents
14.5.6.1.2.7.1.Iodine-based preclinical ct contrast agents
14.5.6.1.2.7.2.Barium-based preclinical ct contrast agents
14.5.6.1.2.7.3.Gold nanoparticles
14.5.6.1.2.7.4.Gastrografin-based preclinical ct contrast agents
14.5.6.1.3.Software
14.5.6.2.Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1.Oncology
14.5.6.2.2.Cardiology
14.5.6.2.3.Neurology
14.5.6.2.4.Infectious diseases
14.5.6.2.5.Immunology and inflammation
14.5.6.2.6.Other Applications
14.5.6.3.Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1.Pharmaceutical and Biotechnology companies
14.5.6.3.2.Academic and Research Centers
14.5.6.3.3.Imaging centers
14.5.6.3.4.Other end users
14.6.Key Segment for Channeling Investments
14.6.1.By Country
14.6.2.By Product Type
14.6.3.By Application
14.6.4.By End User
15.Latin America Preclinical Imaging Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.Latin America Preclinical Imaging Market Revenue (US$ Mn)
15.2.Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
15.2.1.Imaging systems
15.2.1.1.Optical imaging systems
15.2.1.1.1.Bioluminescence imaging systems
15.2.1.1.2.Fluorescence imaging systems
15.2.1.1.3.Other optical imaging systems
15.2.1.2.Nuclear imaging systems
15.2.1.2.1.micro-pet imaging systems
15.2.1.2.2.Micro-spect imaging systems
15.2.1.2.3.Trimodality (spect/pet/ct) imaging systems
15.2.1.3.Micro-MRI systems
15.2.1.4.Micro-ultrasound systems
15.2.1.5.Micro-ct systems
15.2.1.6.Photoacoustic imaging systems
15.2.1.7.Magnetic particle imaging (mpi) systems
15.2.2.Reagents
15.2.2.1.Preclinical optical imaging reagents
15.2.2.2.Preclinical bioluminescent imaging reagents
15.2.2.2.1.Luciferins
15.2.2.2.2.Coelenterazne
15.2.2.2.3.Furimazine
15.2.2.3.Preclinical fluorescent imaging reagents
15.2.2.3.1.Green fluorescent proteins
15.2.2.3.2.Red fluorescent proteins
15.2.2.3.3.Infrared dyes
15.2.2.4.Preclinical nuclear imaging reagents
15.2.2.4.1.Preclinical pet tracers
15.2.2.4.2.Preclinical spect probes
15.2.2.5.Preclinical MRI contrast agents
15.2.2.5.1.Gadolinium-based preclinical contrast agents
15.2.2.5.2.Iron-based preclinical contrast agents
15.2.2.5.3.Manganese-based preclinical contrast agents
15.2.2.6.Preclinical ultrasound contrast agents
15.2.2.7.Preclinical CT contrast agents
15.2.2.7.1.Iodine-based preclinical ct contrast agents
15.2.2.7.2.Barium-based preclinical ct contrast agents
15.2.2.7.3.Gold nanoparticles
15.2.2.7.4.Gastrografin-based preclinical ct contrast agents
15.2.3.Software
15.3.Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1.Oncology
15.3.2.Cardiology
15.3.3.Neurology
15.3.4.Infectious diseases
15.3.5.Immunology and inflammation
15.3.6.Other Applications
15.4.Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
15.4.1.Pharmaceutical and Biotechnology companies
15.4.2.Academic and Research Centers
15.4.3.Imaging centers
15.4.4.Other end users
15.5.Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1.Brazil
15.5.1.1.Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
15.5.1.1.1.Imaging systems
15.5.1.1.1.1.Optical imaging systems
15.5.1.1.1.1.1.Bioluminescence imaging systems
15.5.1.1.1.1.2.Fluorescence imaging systems
15.5.1.1.1.1.3.Other optical imaging systems
15.5.1.1.1.2.Nuclear imaging systems
15.5.1.1.1.2.1.micro-pet imaging systems
15.5.1.1.1.2.2.Micro-spect imaging systems
15.5.1.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
15.5.1.1.1.3.Micro-MRI systems
15.5.1.1.1.4.Micro-ultrasound systems
15.5.1.1.1.5.Micro-ct systems
15.5.1.1.1.6.Photoacoustic imaging systems
15.5.1.1.1.7.Magnetic particle imaging (mpi) systems
15.5.1.1.2.Reagents
15.5.1.1.2.1.Preclinical optical imaging reagents
15.5.1.1.2.2.Preclinical bioluminescent imaging reagents
15.5.1.1.2.2.1.Luciferins
15.5.1.1.2.2.2.Coelenterazne
15.5.1.1.2.2.3.Furimazine
15.5.1.1.2.3.Preclinical fluorescent imaging reagents
15.5.1.1.2.3.1.Green fluorescent proteins
15.5.1.1.2.3.2.Red fluorescent proteins
15.5.1.1.2.3.3.Infrared dyes
15.5.1.1.2.4.Preclinical nuclear imaging reagents
15.5.1.1.2.4.1.Preclinical pet tracers
15.5.1.1.2.4.2.Preclinical spect probes
15.5.1.1.2.5.Preclinical MRI contrast agents
15.5.1.1.2.5.1.Gadolinium-based preclinical contrast agents
15.5.1.1.2.5.2.Iron-based preclinical contrast agents
15.5.1.1.2.5.3.Manganese-based preclinical contrast agents
15.5.1.1.2.6.Preclinical ultrasound contrast agents
15.5.1.1.2.7.Preclinical CT contrast agents
15.5.1.1.2.7.1.Iodine-based preclinical ct contrast agents
15.5.1.1.2.7.2.Barium-based preclinical ct contrast agents
15.5.1.1.2.7.3.Gold nanoparticles
15.5.1.1.2.7.4.Gastrografin-based preclinical ct contrast agents
15.5.1.1.3.Software
15.5.1.2.Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1.Oncology
15.5.1.2.2.Cardiology
15.5.1.2.3.Neurology
15.5.1.2.4.Infectious diseases
15.5.1.2.5.Immunology and inflammation
15.5.1.2.6.Other Applications
15.5.1.3.Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1.3.1.Pharmaceutical and Biotechnology companies
15.5.1.3.2.Academic and Research Centers
15.5.1.3.3.Imaging centers
15.5.1.3.4.Other end users
15.5.2.Argentina
15.5.2.1.Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
15.5.2.1.1.Imaging systems
15.5.2.1.1.1.Optical imaging systems
15.5.2.1.1.1.1.Bioluminescence imaging systems
15.5.2.1.1.1.2.Fluorescence imaging systems
15.5.2.1.1.1.3.Other optical imaging systems
15.5.2.1.1.2.Nuclear imaging systems
15.5.2.1.1.2.1.micro-pet imaging systems
15.5.2.1.1.2.2.Micro-spect imaging systems
15.5.2.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
15.5.2.1.1.3.Micro-MRI systems
15.5.2.1.1.4.Micro-ultrasound systems
15.5.2.1.1.5.Micro-ct systems
15.5.2.1.1.6.Photoacoustic imaging systems
15.5.2.1.1.7.Magnetic particle imaging (mpi) systems
15.5.2.1.2.Reagents
15.5.2.1.2.1.Preclinical optical imaging reagents
15.5.2.1.2.2.Preclinical bioluminescent imaging reagents
15.5.2.1.2.2.1.Luciferins
15.5.2.1.2.2.2.Coelenterazne
15.5.2.1.2.2.3.Furimazine
15.5.2.1.2.3.Preclinical fluorescent imaging reagents
15.5.2.1.2.3.1.Green fluorescent proteins
15.5.2.1.2.3.2.Red fluorescent proteins
15.5.2.1.2.3.3.Infrared dyes
15.5.2.1.2.4.Preclinical nuclear imaging reagents
15.5.2.1.2.4.1.Preclinical pet tracers
15.5.2.1.2.4.2.Preclinical spect probes
15.5.2.1.2.5.Preclinical MRI contrast agents
15.5.2.1.2.5.1.Gadolinium-based preclinical contrast agents
15.5.2.1.2.5.2.Iron-based preclinical contrast agents
15.5.2.1.2.5.3.Manganese-based preclinical contrast agents
15.5.2.1.2.6.Preclinical ultrasound contrast agents
15.5.2.1.2.7.Preclinical CT contrast agents
15.5.2.1.2.7.1.Iodine-based preclinical ct contrast agents
15.5.2.1.2.7.2.Barium-based preclinical ct contrast agents
15.5.2.1.2.7.3.Gold nanoparticles
15.5.2.1.2.7.4.Gastrografin-based preclinical ct contrast agents
15.5.2.1.3.Software
15.5.2.2.Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.2.1.Oncology
15.5.2.2.2.Cardiology
15.5.2.2.3.Neurology
15.5.2.2.4.Infectious diseases
15.5.2.2.5.Immunology and inflammation
15.5.2.2.6.Other Applications
15.5.2.3.Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
15.5.2.3.1.Pharmaceutical and Biotechnology companies
15.5.2.3.2.Academic and Research Centers
15.5.2.3.3.Imaging centers
15.5.2.3.4.Other end users
15.5.3.Rest of Latin America
15.5.3.1.Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Product Type
15.5.3.1.1.Imaging systems
15.5.3.1.1.1.Optical imaging systems
15.5.3.1.1.1.1.Bioluminescence imaging systems
15.5.3.1.1.1.2.Fluorescence imaging systems
15.5.3.1.1.1.3.Other optical imaging systems
15.5.3.1.1.2.Nuclear imaging systems
15.5.3.1.1.2.1.micro-pet imaging systems
15.5.3.1.1.2.2.Micro-spect imaging systems
15.5.3.1.1.2.3.Trimodality (spect/pet/ct) imaging systems
15.5.3.1.1.3.Micro-MRI systems
15.5.3.1.1.4.Micro-ultrasound systems
15.5.3.1.1.5.Micro-ct systems
15.5.3.1.1.6.Photoacoustic imaging systems
15.5.3.1.1.7.Magnetic particle imaging (mpi) systems
15.5.3.1.2.Reagents
15.5.3.1.2.1.Preclinical optical imaging reagents
15.5.3.1.2.2.Preclinical bioluminescent imaging reagents
15.5.3.1.2.2.1.Luciferins
15.5.3.1.2.2.2.Coelenterazne
15.5.3.1.2.2.3.Furimazine
15.5.3.1.2.3.Preclinical fluorescent imaging reagents
15.5.3.1.2.3.1.Green fluorescent proteins
15.5.3.1.2.3.2.Red fluorescent proteins
15.5.3.1.2.3.3.Infrared dyes
15.5.3.1.2.4.Preclinical nuclear imaging reagents
15.5.3.1.2.4.1.Preclinical pet tracers
15.5.3.1.2.4.2.Preclinical spect probes
15.5.3.1.2.5.Preclinical MRI contrast agents
15.5.3.1.2.5.1.Gadolinium-based preclinical contrast agents
15.5.3.1.2.5.2.Iron-based preclinical contrast agents
15.5.3.1.2.5.3.Manganese-based preclinical contrast agents
15.5.3.1.2.6.Preclinical ultrasound contrast agents
15.5.3.1.2.7.Preclinical CT contrast agents
15.5.3.1.2.7.1.Iodine-based preclinical ct contrast agents
15.5.3.1.2.7.2.Barium-based preclinical ct contrast agents
15.5.3.1.2.7.3.Gold nanoparticles
15.5.3.1.2.7.4.Gastrografin-based preclinical ct contrast agents
15.5.3.1.3.Software
15.5.3.2.Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.2.1.Oncology
15.5.3.2.2.Cardiology
15.5.3.2.3.Neurology
15.5.3.2.4.Infectious diseases
15.5.3.2.5.Immunology and inflammation
15.5.3.2.6.Other Applications
15.5.3.3.Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1.Pharmaceutical and Biotechnology companies
15.5.3.3.2.Academic and Research Centers
15.5.3.3.3.Imaging centers
15.5.3.3.4.Other end users
15.6.Key Segment for Channeling Investments
15.6.1.By Country
15.6.2.By Product Type
15.6.3.By Application
15.6.4.By End User
16.Competitive Benchmarking
16.1.Brand Benchmarking
16.2.Market Share Analysis, 2023
16.3.Global Presence and Growth Strategies
16.3.1.Mergers and Acquisitions
16.3.2.Product Launches
16.3.3.Investments Trends
16.3.4.R&D Initiatives
17.Player Profiles
17.1.Agilent Technologies
17.1.1.Company Details
17.1.2.Company Overview
17.1.3.Product Offerings
17.1.4.Key Developments
17.1.5.Financial Analysis
17.1.6.SWOT Analysis
17.1.7.Business Strategies
17.2.Bruker Corporation
17.2.1.Company Details
17.2.2.Company Overview
17.2.3.Product Offerings
17.2.4.Key Developments
17.2.5.Financial Analysis
17.2.6.SWOT Analysis
17.2.7.Business Strategies
17.3.General Electric (GE)
17.3.1.Company Details
17.3.2.Company Overview
17.3.3.Product Offerings
17.3.4.Key Developments
17.3.5.Financial Analysis
17.3.6.SWOT Analysis
17.3.7.Business Strategies
17.4.Mediso Ltd.
17.4.1.Company Details
17.4.2.Company Overview
17.4.3.Product Offerings
17.4.4.Key Developments
17.4.5.Financial Analysis
17.4.6.SWOT Analysis
17.4.7.Business Strategies
17.5.MILabs B.V.
17.5.1.Company Details
17.5.2.Company Overview
17.5.3.Product Offerings
17.5.4.Key Developments
17.5.5.Financial Analysis
17.5.6.SWOT Analysis
17.5.7.Business Strategies
17.6.Molecubes
17.6.1.Company Details
17.6.2.Company Overview
17.6.3.Product Offerings
17.6.4.Key Developments
17.6.5.Financial Analysis
17.6.6.SWOT Analysis
17.6.7.Business Strategies
17.7.MR Solutions
17.7.1.Company Details
17.7.2.Company Overview
17.7.3.Product Offerings
17.7.4.Key Developments
17.7.5.Financial Analysis
17.7.6.SWOT Analysis
17.7.7.Business Strategies
17.8.PerkinElmer, Inc.
17.8.1.Company Details
17.8.2.Company Overview
17.8.3.Product Offerings
17.8.4.Key Developments
17.8.5.Financial Analysis
17.8.6.SWOT Analysis
17.8.7.Business Strategies
17.9.Siemens A.G.
17.9.1.Company Details
17.9.2.Company Overview
17.9.3.Product Offerings
17.9.4.Key Developments
17.9.5.Financial Analysis
17.9.6.SWOT Analysis
17.9.7.Business Strategies
17.10.TriFoil Imaging
17.10.1.Company Details
17.10.2.Company Overview
17.10.3.Product Offerings
17.10.4.Key Developments
17.10.5.Financial Analysis
17.10.6.SWOT Analysis
17.10.7.Business Strategies
17.11.VisualSonics Inc. (Fujifilm)
17.11.1.Company Details
17.11.2.Company Overview
17.11.3.Product Offerings
17.11.4.Key Developments
17.11.5.Financial Analysis
17.11.6.SWOT Analysis
17.11.7.Business Strategies
17.12.Other Industry Participants
18.Key Findings

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

Global Preclinical Imaging Market

By Product Type

  • Imaging systems
    • Optical imaging systems
      • Bioluminescence imaging systems
      • Fluorescence imaging systems
      • Other optical imaging systems
    • Nuclear imaging systems
      • micro-pet imaging systems
        • Standalone pet imaging systems
        • Pet/CT imaging systems
        • Pet/MRI imaging systems
      • Micro-spect imaging systems
        • standalone spet imaging systems
        • spet/ct imaging systems
        • spet/ MRI imaging systems
      • Trimodality (spect/pet/ct) imaging systems
    • Micro-MRI systems
    • Micro-ultrasound systems
    • Micro-ct systems
    • Photoacoustic imaging systems
    • Magnetic particle imaging (mpi) systems
  • Reagents
    • Preclinical optical imaging reagents
    • Preclinical bioluminescent imaging reagents
      • Luciferins
      • Coelenterazne
      • Furimazine
    • Preclinical fluorescent imaging reagents
      • Green fluorescent proteins
      • Red fluorescent proteins
      • Infrared dyes
    • Preclinical nuclear imaging reagents
      • Preclinical pet tracers
        • Fluorine-18-based preclinical pet tracers
        • Carbon-11-based preclinical pet tracers
        • Copper-64-based preclinical pet tracers
        • Other pet tracers
      • Preclinical spect probes
        • Technetium-99m-based preclinical spect probes
        • Iodine-131-based preclinical spect probes
        • Gallium-67-based preclinical spect probes
        • Thallium-201-based preclinical spect probes
        • Other spect probes
      • Preclinical MRI contrast agents
        • Gadolinium-based preclinical contrast agents
        • Iron-based preclinical contrast agents
        • Manganese-based preclinical contrast agents
      • Preclinical ultrasound contrast agents
      • Preclinical CT contrast agents
        • Iodine-based preclinical ct contrast agents
        • Barium-based preclinical ct contrast agents
        • Gold nanoparticles
        • Gastrografin-based preclinical ct contrast agents
      • Software

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Infectious diseases
  • Immunology & inflammation
  • Other Applications

By End User

  • Pharmaceutical & biotechnology companies
  • Academic & research centers
  • Imaging centers
  • Other end users

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global Preclinical Imaging Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top